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Abstract 
Under the most ideal circumstances, anticancer agents should be minimally toxic 
to normal cells and maximally noxious to cancer cells. Unfortunately, an optimal degree 
of selectivity is not typically achieved and chemotherapy is often prematurely stopped 
due to potentially life threatening side effects. For this reason, various approaches have 
been explored in an attempt to enhance the selectivity of anticancer drugs. For the most 
part, these techniques are based on Paul Ehrlich‘s concept of a ―magic bullet‖ which is 
the attempt to target drugs to a disease site while avoiding healthy tissues. These 
approaches therefore share a common requirement that the active drug achieves greater 
concentration in or around tumor cells relative to normal cells. However, many of these 
approaches have achieved limited success due to the difficulty of achieving site-specific 
accumulation of conventional anticancer agents. 
A rarely considered option in enhancing drug selectivity lies in optimizing the 
intracellular distribution of drugs to achieve favorable distribution in cancer cells (i.e. in 
compartments that allow drug-target interactions), and unfavorable distribution in normal 
cells (i.e. in compartments that diminish drug-target interactions), essentially an 
intracellular drug distribution-based (IDB) targeting approach. The IDB targeting 
approach presents a paradigm shift from the classical approaches to enhance selectivity, 
since the active drug is not expected to achieve higher concentrations in cancer cells 
relative to normal cells. Instead the drug accumulates to the same extent in both normal 
and cancer cells, but the aforementioned differences in intracellular drug distribution 
result in selectivity.  
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In the work presented here, we investigated whether the defective lysosomal 
acidification associated with some cancer cells can be exploited to enhance selectivity of 
weakly basic anticancer agents. Normal cells typically have very acidic lysosomes, which 
provide a driving force for the accumulation of weakly basic drugs (with appropriate 
physicochemical properties) into lysosomes. Some cancer cells have been shown to have 
defective acidification of lysosomes, leading to a reduction in the extent of lysosomal 
trapping of such weakly basic drugs. Our hypothesis is that the reduced sequestration of 
weakly basic drugs in lysosomes of cancer cells would increase cytosolic drug 
concentration, thus enhancing drug-target interactions, compared to the case in normal 
cells, where extensive sequestration would diminish drug-target interactions. We 
proposed that these differences in drug localization patterns between normal and cancer 
cells, and the resultant difference in drug activity, would enhance selectivity of 
lysosomotropic anticancer drugs to cancer cells.  
In order to establish the potential for broad therapeutic application of this 
approach, we assessed the prevalence of defective lysosomal acidification in cancer cells, 
and whether lysosomal targeting of anticancer drugs could reduce their systemic toxicity. 
We also evaluated whether IDB selectivity can be optimized according to relevant 
physicochemical parameters of drug candidates, specifically the ionization constant 
(pKa). These evaluations provide a rationale for the design or modification of anticancer 
drugs with physicochemical properties that maximize lysosomal trapping in order to 
enhance selectivity. 
Collectively, our results demonstrate that drugs with optimal lysosomotropic 
properties are more selective to cells with defective lysosomal acidification. Therefore, 
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intracellular drug-distribution based (IDB) targeting provides a viable approach to 
enhance anticancer drug selectivity. As mentioned previously, the major limitation to 
enhancing selectivity through site-directed targeting of conventional anticancer drugs to 
tumors is the difficulty of achieving site-specific localization. Enhancing selectivity 
through IDB targeting represents a rational approach that will not be subject to the 
limitations faced by site-directed targeting approaches since there is no requirement that 
drugs achieve tumor-specific localization. 
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1.1. Introduction 
Ideally, anti-cancer drugs should be minimally toxic to normal cells and 
maximally noxious to cancer cells. Unfortunately, an optimal degree of selectivity is not 
typically achieved and chemotherapy is often prematurely stopped due to potentially life 
threatening damage to normal tissues and organs [1,2]. A great deal of research has been 
carried out on developing methods to improve the selectivity of existing anticancer drugs. 
Many such approaches are based on the ‗magic bullet‘ approach, first envisioned by Paul 
Ehrlich as a means to target drugs to a disease site while avoiding healthy tissues [3]. 
Accordingly, all of these approaches share a common requirement in that the active drug 
is expected to accumulate to a greater extent in or around cancer cells, relative to normal 
cells. To this end, a number of creative drug delivery strategies have been tested, e.g. 
drugs conjugated to tumor targeting moieties and site-activated prodrugs. However, the 
therapeutic usefulness of these approaches have been somewhat limited [3].  
An important, but rarely considered variable in drug design is the intracellular 
distribution of therapeutic agents. Since cells are highly compartmentalized, drugs as well 
as drug targets are often localized in distinct compartments. For a drug to exert a 
therapeutic response it must interact with its target, hence it has to localize in the same 
compartment as its target. It is now well understood that physicochemical properties of 
drugs influence their intracellular distribution [4,5,6]. Drug properties can therefore be 
optimized to achieve the most favorable intracellular localization in target cells. It is 
conceptually feasible to develop a selectivity approach that relies on differences in 
intracellular drug distribution between normal and target (cancer) cells, contingent upon 
differences in sub-cellular features between the cell types that could influence drug 
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distribution. Such an approach would require that the drug achieve favorable distribution 
in target cells (i.e. in compartments that allow drug-target interactions), and unfavorable 
distribution (in compartments that diminish drug-target interactions) in normal cells. A 
schematic representation of this approach is shown in Figure 1.1, for a drug with a 
cytosolic target. In normal cells the drug would be localized in compartments distinct 
from the cytosol, thus preventing drug-target interactions, while in target cells it would be 
localized in the cytosol, thus promoting drug-target interactions.  
One of the most prevalent intracellular drug distribution phenomena is the 
lysosomal sequestration of weak bases, which has been shown to occur with numerous 
weakly basic drugs [7,8,9]. Lysosomal sequestration occurs via ion trapping, whereby the 
accumulation of weak bases from the cytosol into lysosomes is driven by the lysosome-
to-cytosol pH gradient. While the cytosolic pH is typically close to neutral, the pH of 
lysosomes in normal cells is typically very acidic, with pH values around 4-4.5. This 
creates a large lysosome-to-cytosol pH gradient that drives the extensive accumulation of 
weakly basic drugs (with optimal physicochemical properties) into lysosomes. The 
theoretical principles of ion-trapping were first introduced by Christian de Duve [8], and 
will be discussed in mechanistic detail in a subsequent section of this chapter. 
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targettarget
 
 
Figure 1.1. A schematic representation of an intracellular drug-distribution-based 
approach to enhance selectivity. In the normal cell (left), the drug (represented by red 
dots) is localized in a compartment distinct from the target-containing compartment, thus 
minimizing drug-target interactions. In the target cell, a greater concentration of the drug 
is localized in the target containing compartment, thus enhancing drug target interactions 
and drug activity. 
 
Interestingly, we and others have shown that some cancer cells have defective 
acidification of lysosomes [10,11,12,13]. This reduces the lysosome-to-cytosol pH 
gradient, hence lowering the propensity for weak bases to be sequestered in lysosomes of 
cancer cells. Therefore, compared to the case in normal cells, weakly basic drugs will 
have a greater localization in extralysosomal compartments of cancer cells. We propose 
that these differences in drug distribution between normal and cancer cells can provide 
the basis for intracellular drug distribution-based (IDB) drug selectivity, since the degree 
of lysosomal sequestration will directly influence the amount of drug available to interact 
with the drug target. Since anticancer drug targets are not typically localized in 
lysosomes, the reduced lysosomal trapping will enhance drug-target interactions in 
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cancer cells. In normal cells however, extensive lysosomal sequestration will minimize 
the degree of drug interaction with targets, thereby reducing drug activity.   
The overall objective of this dissertation is to evaluate the feasibility of the 
intracellular drug distribution-based approach to enhance selectivity of anticancer drugs, 
specifically, whether the lysosomal acidification defect associated with some cancer cells 
can be exploited to enhance anticancer drug selectivity. In order to establish the potential 
for therapeutic applicability of the IDB targeting approach to a broad spectrum of cancer 
types, we evaluated the prevalence of defective acidification of lysosomes as outlined in 
Chapter 2. In Chapter 3, we investigated whether IDB selectivity of lysosomotropic drugs 
can be optimized according to the ionization constant (pKa) of the weak base, which is a 
key physicochemical parameter influencing lysosomal sequestration. Since the ultimate 
goal of enhancing specificity of anticancer drugs is to reduce systemic toxicity of the 
parent drug, in Chapter 4 we evaluated the role of lysosomal sequestration on drug 
toxicity in vivo. 
The indiscriminate toxicity of anticancer drugs to cancer cells and normal cells 
alike is due in part to traditional anticancer drug discovery approaches. The traditional 
empirical approach to cancer drug discovery contributes to a drug identification process 
that is skewed toward potent drugs that have poor selectivity. Therefore, in this chapter 
we discuss the early development of anticancer drugs and how this could contribute to 
their high toxicity.  
The indiscriminate toxicity of anticancer agents has led to a variety of research 
efforts into drug delivery approaches that could enhance their selectivity. In general, the 
classical approaches to enhance anticancer drug selectivity require that the active drug 
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achieves a higher concentration around cancer cells relative to normal cells. Some of 
these approaches will be discussed herein, as well as specific and general reasons why 
they have not yielded an effective and generally applicable route to reducing the toxicity 
associated with anticancer drugs. Many of the factors that limit the success of classical 
drug targeting approaches stem from the difficulty in achieving truly site-specific drug 
delivery, a limitation that would not be encountered by an IDB targeting approach. 
Therefore, if the IDB targeting approach to enhance selectivity is feasible and applicable 
to a range of cancer types, it will result in significant gains in improving the therapeutic 
efficacy of anticancer drugs. 
 
1.2. A historical perspective of anticancer drug discovery 
The toxicity of traditional anticancer drugs can be explained in part by the empirical 
nature of early anticancer drug development. Most early anticancer drug candidates were 
pursued based on evidence of toxicity, without an understanding of their molecular 
mechanism of action [14]. For instance, it was due to the toxic effects of the chemical 
weapon sulfur mustard, originally synthesized in 1854 and used in World War I that 
anticancer drugs were discovered [15]. In World War II soldiers accidentally exposed to 
sulfur mustard at Bari Harbor, Italy suffered from severe irritation of the respiratory tract 
and eye, and it was soon recognized that the toxic effects of sulfur mustard targeted the 
rapidly dividing cells of the gastrointestinal tract and blood forming organs [15,16]. The 
selective toxicity of sulfur mustard to rapidly dividing cells led to the postulation that 
rapidly dividing tumor cells would likewise be highly susceptible to similar agents. 
Subsequently, researchers at Yale carried out successful experiments using nitrogen 
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mustard against a murine lymphoid tumor that demonstrated its efficacy against tumor 
growth [16]. Later, nitrogen mustard was administered to patients with non-Hodgkins 
lymphoma [15], whereby the drug was found to induce marked tumor regression.  
The discovery of nitrogen mustard as a novel anticancer drug resulted in a great deal 
of optimism that cancer could finally be cured. A burst of research activity to develop 
new anticancer drugs therefore resulted, which yielded thousands of additional 
compounds with potent anti-tumor activity [16]. The major obstacle to further cancer 
drug discovery became the lack of an appropriate model to test this vast array of new 
anticancer compounds and identify the ones with therapeutic potential. In 1935, Murray 
Shear of the United States Public Health Service developed the first anticancer drug 
screening model, which consisted of murine tumor cells, since the culture of human cells 
had not been successfully accomplished at the time. Of three thousand compounds 
initially tested by Shear, only two made it to clinical trials, but were eventually dropped 
due to unacceptable toxicity [16].  
The early use of fast-growing murine tumor models resulted in a vast majority of 
anticancer drugs selected in these early discovery programs being anti-proliferative [15]. 
Such drugs have an inherent selectivity to cancer cells due to the typically enhanced rate 
of cell division characteristic of many cancer types. However, there are a host of normal 
cells that undergo a rapid turnover, particularly cells of the gastrointestinal tract, hair 
follicles and bone marrow, which proliferate almost as rapidly as any growing tumor 
[17]. For this reason, anti-proliferative cancer drugs will be just as active in these types of 
normal cells, resulting in the typical side effects of chemotherapy such as nausea, hair 
loss and immune suppression. 
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Over the years, the screening model used in the evaluation of new anti-cancer drugs 
has evolved from the use of murine cancer types to the currently used NCI-60 cell line 
screen, a panel of 60 human cancer cells lines representing various tumor types (both fast 
and slow growing cells of varied lineage) that was developed to provide a more 
therapeutically relevant screening model [18]. Although this screening model is 
instrumental in the identification and development of potent anti-cancer drugs, it fails to 
identify potent anticancer drugs with a concomitant lack of activity against normal cells. 
Indeed, many novel anticancer agents continue to be identified, but few find clinical 
utility due to unacceptable toxicity [17], a clear indicator that there is a need for a 
screening approach that can identify potent drugs with reduced activity in normal cells 
very early in the anticancer drug development process.  
Given the high concentration of drug required to achieve tumor regression, the dose-
limiting toxicity of anticancer drugs inevitably poses a challenge to successful 
chemotherapy. Most efforts to enhance the selectivity of existing anticancer drugs have 
focused on enhancing delivery of the active drug to cancer cells, while attempting to limit 
accumulation around normal cells. Some of these classical approaches are reviewed 
subsequently. 
 
1.3. Classical strategies to enhance cancer drug selectivity 
In general, a tumor targeting drug-delivery system consists of a derivative of the 
parent drug that incorporates a tumor recognition moiety that targets cancer cells [3], 
which should ideally be inactive until delivery to the tumor site is achieved. Tumor 
targeting is made possible by the existence of various biochemical and phenotypic 
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differences between normal and cancer cells [19,20,21]. For example, rapidly growing 
tumors tend to have an increased need for certain nutrients, vitamins and growth factors 
[22,23], and therefore have an enhanced uptake of such molecules relative to normal cells 
[24]. Phenotypic differences between normal and cancer cells may include receptors or 
proteins that are expressed on the plasma membranes of tumor cells but are minimally 
present or absent from normal cells [19]. Lastly, the tumor vasculature [25] and 
microenvironment [26] also have features distinct from that of normal tissue, which could 
be exploited to enable tumor specific delivery.  
Classical drug delivery strategies that have been explored to enhance the 
selectivity of anticancer drugs include conjugating drugs to antibodies that can recognize 
tumor specific antigens [19,27], or conjugating drugs to molecules that are taken up at a 
higher rate by cancer cells relative to normal cells, such as folic acid [28]. Passive 
targeting to tumor cells of a drug that is anchored to or encapsulated in an appropriately 
sized carrier can be achieved due to defects in tumor vasculature and lymphatic drainage, 
which allow the carrier to accumulate and be retained to a greater extent in tumor tissue 
relative to normal tissues [29]. Prodrugs that can be selectively activated by enzymes, or 
other features unique to the tumor environment, are yet another approach to achieve site 
specific localization of an active anticancer drug [30,31]. 
These conventional approaches to enhance tumor targeting of cancer drugs are 
discussed in the following section. Although a discussion of all the drug delivery 
approaches that have been explored for improving cancer drug selectivity is outside the 
scope of this dissertation, they are for the most part similar in principle to the examples 
discussed here.  
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1.3.1. Tumor-targeting drug conjugates 
 The principle of this approach is that an active drug can be conjugated to a tumor 
targeting moiety that ideally, will allow a drug that is administered systemically to 
localize specifically around tumor tissue. This can be achieved either by conjugating a 
drug to a moiety that will recognize tumor-specific molecules, or conjugation to 
molecules preferentially taken up by cancer cells. Some examples of this approach are as 
follows: 
Antibody-drug conjugates: The presence of antigens on the surface of tumor cells 
that are absent, or minimally present on the surfaces of normal cells [19] makes it 
possible to conjugate drugs to antibodies that can deliver drugs selectively to such tumor 
cells. These tumor associated antigens (TAAs) may include gangliosides, glycoproteins, 
growth factor receptors and oncoproteins [19,32,33]. Antibodies that recognize these 
antigens can be conjugated to cytotoxic agents, via linkers that should ideally be stable 
until the conjugate is specifically delivered to the tumor site, in order to avoid premature 
release of the drug [34].  
The concept of antibody drug targeting is theoretically very appealing, since a 
highly specific antibody should be capable of targeting the drug very efficiently to the 
tumor site. However, the reality is that the success of this approach has been quite 
modest. Many antibodies bind to some extent to antigens expressed on normal cells as 
well [34], thus reducing the specificity of targeting. The number of molecules that can be 
conjugated to an antibody is limited by the need to preserve the activity of the antibody, 
therefore drug-antibody conjugates often fail to deliver an effective concentration of drug 
to the tumor site [35]. Moreover, the sheer size of antibodies hinders the penetration of 
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antibody drug conjugates into solid tumors. In fact, it has been shown that only about 1% 
of dosed antibody typically reaches the tumor site [17]. 
In a clear indicator of the challenges facing this approach, the only FDA approved 
antibody-drug conjugate for cancer treatment-gemzutumab ozogamicin (Mylotarg®), 
licensed for treatment of AML [36], was recently withdrawn from market due to 
unacceptable toxicity. [37]. Mylotarg is an antibody drug conjugate consisting of a 
humanized mAb, P67.6, conjugated via a hydrazone and a disulfide linker to the highly 
cytotoxic agent N-acetyl-calicheamicin, which is released intracellularly upon lysosomal 
cleavage of the hydrazone linker [30]. The withdrawal of Mylotarg was necessitated by 
its high degree of systemic toxicity, including myelosuppression, thrombocytopenia, and 
nausea [36]. 
Although antibody-drug conjugates are a rational and conceptually appealing 
approach to enhance tumor drug delivery, they are faced with a number of limitations, as 
mentioned, which have limited their utility. Besides these limitations, they may face other 
issues such as stability concerns necessitating complex formulation. 
 
Folic acid-drug conjugates: Tumor cells have been found to require more folic 
acid, and to have a higher affinity for it than normal cells [38] , since it is required for 
DNA and RNA synthesis [39]. The folate receptor is therefore overexpressed in a number 
of cancers including ovarian cancer [38,40], colon carcinoma [38]  and osteosarcoma 
[41]. Folic acid is therefore an attractive choice as a tumor targeting moiety, and has been 
conjugated to various drugs for this purpose. Leamon and Low were the first to exploit 
folic acid as a so called ‗trojan horse‘ to deliver anticancer agents into cancer cells [42], 
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and since then a number of other drugs conjugated to folic acid have been described. Lee 
et al. attached folic acid to paclitaxel through an oligoethyleneylglycol linker [43]. 
However, they found that the folate receptor binding affinity of a representative 
conjugate, C-7-(PEG-3)-folyl paclitaxel, to FR positive KB cells was only 1/4 that of free 
folic acid. The successful in vivo evaluation of folic-acid conjugated to a proprietary 
cytotoxic warhead has been described by Leamon and Ready [42]. The conjugate is 
reported to have exhibited enhanced activity against human KB xenografts and reduced 
systemic toxicity.  
 Although folic acid has been lauded as a model tumor targeting moiety, since its 
small size allows penetration into solid tumors, and prevents an immune response [28], so 
far there is no approved folic acid-drug conjugate for tumor targeting, although some 
advancement has been made in the use of folic acid to target radio-imaging agents to 
tumors [27]. 
 
Peptide-drug conjugates: Tumor targeting with peptides is feasible based on the 
finding that receptors of many regulatory peptides are overexpressed in tumor cells 
compared to normal tissues [44,45,46]. An example is the somatostatin membrane 
receptor (SSTR), which binds to the neuropeptide somatostatin (SST) with a very high 
affinity [27]. Therefore, SST and its analogs can be applied as tumor targeting moieties, 
and a few such approaches have been described. Sun et al. described the conjugation of a 
somatostatin analog to camptothecin [47], which exhibited anti-angiogenic and anti-
invasive properties, but had no appreciable activity against the cancer cell line tested (PC-
3 prostate cancer). The authors predicted an improvement of systemic toxicity of the 
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conjugate, but did not evaluate this conclusion in vivo. Conjugation of doxorubicin and a 
super-active doxorubicin derivative, 2-pyrrolino-DOX to somatostatin has been described 
by Nagy and co-workers [48]. These conjugates retained cytotoxic activity and were less 
toxic in vivo than the parent compounds. Another peptide with potential for drug 
targeting is luteinizing hormone-releasing hormone (LHRH), whose receptor has also 
been found to be overexpressed in some cancer types relative to normal cells [49]. A 
number of reports of LH-RH-anticancer drug analogues have also been described [50]. 
Conjugation of drugs to bombesin, a homolog of gastrin-releasing peptide (GRP), whose 
receptors have also been found to be overexpressed in some cancer cells [51,52] has also 
been explored. 
Despite some promise, the use of peptides in drug targeting is hampered by their 
short-half-life in blood and generally poor bioavailability [53]. Chemical modification is 
often necessary to increase the serum stability of peptides, but such modified peptides 
may be more immunogenic. 
 
Poly-unsaturated fatty acid-drug conjugates: Several studies have shown that -
poly unsaturated fatty acids (PUFAs) stimulate several stages in the development of 
cancer [54]. Cancer cells appear to take up PUFAs at a higher rate than normal cells, 
presumably for use as biochemical precursors and energy sources [55]. Therefore, 
PUFAs are potential vehicles for selective delivery of drugs to cancer cells, especially 
since they are naturally occurring in many foods and are hence regarded as safe. Some 
naturally occurring PUFAs found in the diet are linolenic acid (LNA), linoleic acid (LA), 
arachidonic acid (AA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA). 
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Bradley et al. conjugated DHA to the C-2′ position of paclitaxel, achieving a derivative 
(Taxoprexin) that exhibited substantially increased antitumor activity and reduced 
systemic toxicity as compared to paclitaxel [56]. However, Ojima and co-workers argue 
that the released Paclitaxel would be a prime candidate for extrusion by Pgp activity, and 
would therefore not be effective against drug resistant cancer cells. As an alternative, this 
group developed so-called second generation taxoids with reduced Pgp activity and 
enhanced anti-tumor activity and conjugated these drugs to DHA and α-LA to create 
conjugates with reduced systemic toxicity in mice [57].  
 
Hyaluronic acid-drug conjugates: Hyaluronic acid (HA), or hyaluronan is a high 
molecular weight compound found particularly in loose connective tissue [58]. It has a 
number of functions in the extracellular matrix, and has been shown to be elevated in 
various cancers, including breast, ovarian, prostrate and colorectal cancers [59]. The 
elevated expression of HA in tumors has been associated with increased tumor cell 
migration and metastasis [60,61]. Tumor cells also overexpress HA receptors such as the 
cell surface glycoprotein CD44 [62], and the receptor for hyaluronic acid-mediated 
motility, CD168 [63]. Therefore, conjugation of HA to various cytotoxics has potential 
for enhanced site specific delivery of drugs to tumor sites. HA conjugated drugs are taken 
up into the cell via receptor-mediated endocytosis followed by intracellular degradation 
of HA and release of active drug [64]. This approach has been described for enhancing 
tumor delivery of doxorubicin [64] paclitaxel [65] and butyric acid [66]. This approach is 
however limited by the fact that only a few drug molecules can be conjugated to HA. 
Highly loaded HA-drug conjugates were found to have poor cellular uptake due to 
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reduced affinity to the HA receptor [66]. This limitation would greatly reduce the 
concentration of active drug that could be delivered to the tumor site. 
 
1.3.2. Site activated prodrugs   
A prodrug is a bioreversible derivative of a molecule, which is designed to 
overcome the barrier or barriers to the utility of the said molecule [26]. The 
indiscriminate toxicity of anticancer drugs presents a barrier to their efficacy, which can 
be overcome by the use of site-activated prodrugs, which would ideally be inactive until 
selectively activated or released at the tumor site. Characteristics unique to the tumor 
microenvironment such as low pH, hypoxia and tumor specific enzymes [26] have been 
exploited to provide routes to site-specific activation of prodrugs. The low pH around 
tumors is caused by increased production of lactic acid due to anaerobic respiration [67]. 
A few instances of pH-activated anti-tumor prodrugs have been described. For example, 
Tomlinson et al. conjugated doxorubicin to a hydrolytically-labile amino-pendent 
polyacetal with pH-dependent degradation [68].  
In order to invade other tissues and metastasize, tumor cells tend to have an 
increased production of proteolytic enzymes, which break down the extracellular matrix 
to allow cell migration [69]. Such enzymes can provide a route to tumor-specific 
activation of prodrugs, since they do not exist or are minimally present around normal 
tissues. Some of these enzymes include β-glucuronidase, matrix metalloproteinases and 
cathepsin B which can cleave the tumor specifying moiety from the protease cleavable 
prodrug [30]. A majority of enzyme activated prodrugs have a releasable linker between 
the tumor specifier and the drug, which reduces steric hindrance to cleavage of the 
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targeting moiety [30]. Since, most enzymes are not usually distributed in a consistent 
manner in tumors, an alternative approach is to target the activating enzyme to the tumor 
site using antibodies to tumor antigens, an approach known as antibody directed enzyme 
prodrug therapy (ADEPT).  
Hypoxic conditions in the tumor microenvironment, which are a consequence of 
the malformed structure of the tumor vasculature leading to low oxygenation [26], can be 
exploited to enhance the tumor specificity of bioreductive anticancer prodrugs. 
Bioreduction occurs via enzymes that are also present in normal tissues; however 
complete reduction to the active agent occurs in the absence of oxygen, thus imparting 
tumor specificity of activation. A number of hypoxia-activated anti-cancer prodrugs have 
been described that are activated through reduction of applicable moieties such as 
quinones N-oxides and heteroaromatic nitro groups [30] .  
A disadvantage of site-activated prodrugs is that premature cleave of the cytotoxic 
agent can lead to systemic toxicity. Secondly, for pH activated prodrugs, the difference in 
extracellular pH between normal and tumor tissue is typically quite small (~0.4 units), 
which is a very narrow range to attempt to exploit for selective activation in tumor tissue.  
 
1.3.3. Passive tumor targeting via the EPR effect 
 The enhanced permeability and retention (EPR) effect refers to the enhanced 
accumulation of macromolecules in tumor tissue due to the characteristic increased 
permeability of tumor blood vessels, and enhanced retention due to poor lymphatic 
drainage [29]. To obtain nutrients for growth, and to metastasize, tumors often co-opt 
existing blood vessels, and recruit endothelial cells from bone marrow to grow new ones 
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[70], thus creating a vasculature that is structurally abnormal and functionally impaired, 
with haphazardly interconnected blood vessels. To aid in the sprouting of new blood 
vessels, vascular endothelial growth factor (VEGF), a key regulator of vascular 
permeability [71,72] is often overexpressed in solid tumors, leading to an overly 
permeable, ‗leaky‘ tumor vasculature. This allows large molecules, ranging from 10 to 
100nm in size, to be released from the tumor vasculature into the tumor interstitial space 
[73]. Impaired lymphatic drainage enhances retention of the drug-carrying 
macromolecule at the tumor site. This phenomenon, termed enhanced permeability and 
retention (EPR), first described by Maeda et al.[29], allows large molecules to 
‗extravasate‘ from the blood vessels into the tumor and become trapped within the tumor 
region [74]. This phenomenon creates the opportunity to load molecules of a certain size 
with cytotoxic drugs and ensures that delivery is restricted to tumor sites, since normal 
vasculature does not allow molecules of this size to exit blood vessels [75]. For tumor 
selective drug delivery, the EPR effect has been exploited to enhance delivery of drugs 
conjugated to macromolecules, and particulate carriers such as liposomes [76]. 
 
1.4. Limitations to site-specific drug targeting  
Despite the creativity of the above approaches to achieve anticancer drug 
selectivity, the ‗magic bullet‘ for cancer therapy is yet to be discovered. Site directed 
targeting has achieved only modest advances in reducing the toxicity of available anti-
cancer drugs, and has so far failed to produce an effective and generally applicable site-
specific drug delivery system [3]. There are several limitations contributing to the lack of 
success of tumor directed targeting, some of which were discussed specifically for each 
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of the targeting approaches described above. However, the overriding obstacle to the 
success of these approaches is the difficulty in achieving site-specific delivery of the 
traditional anticancer drugs employed in these approaches. The very nature of 
conventional therapeutics (low molecular weight, lipophilicity) which allows them to 
traverse cells membranes and accumulate in cells, also renders them highly likely to 
diffuse away from targeted sites following site-specific delivery [77]. Therefore, it is not 
that drug targeting completely fails to achieve site specific accumulation at the site, rather 
delivered drugs are not retained at the site. The general conclusion is that drugs for site-
directed targeting must have physicochemical features that will allow them to be retained 
at the desired site of delivery [78]. In addition, successful delivery of a drug targeting 
vessel or carrier to the target organ may not guarantee that an adequate amount of the free 
drug will be available at the actual targets (which for most anticancer drugs are 
intracellular). Additional processes such as active/passive transport across the cell 
membrane, release from carriers, and metabolism will influence the overall outcome [3] 
and must separately be studied and optimized. 
 An additional consideration is whether the additional cost that is inevitably 
associated with the production of drug-conjugates justifies their use. An approach that 
would obviate this concern was briefly alluded to in the introduction and is based on the 
optimization of intracellular drug distribution to achieve the desired activity in cancer 
cells and not in normal cells. The intracellular drug distribution-based selectivity 
approach proposes modifications on the chemical structure of a drug that can influence 
intracellular distribution by altering the physicochemical properties of the drug, while 
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having minimal impact on cell uptake, tumor penetration and activity of the drug. The 
principles and mechanism of this approach is discussed in the next section. 
 
1.5. Intracellular drug distribution and implications for drug activity and selectivity 
 The previously described approaches to enhance selectivity of anticancer drugs all 
rely on targeting the active anticancer drug to the vicinity of cancer cells while avoiding 
drug delivery to normal cells. However, an often overlooked variable in determining drug 
effectiveness is the intracellular distribution and localization of drugs. Several studies 
have addressed how structural and physicochemical properties can influence the 
intracellular distribution of drugs [6]. For example, lipophilic compounds with a 
delocalized positive charge are known to localize in mitochondria due to the organelle‘s 
negative membrane potential [79]. Planar aromatic compounds such as anthracyclines are 
have a high binding affinity to DNA base pairs and therefore predominantly localize in 
the nucleus [6]. 
Just as drugs may localize in any of several compartments, drug targets also 
typically have well-defined intracellular localization sites. Many cancer drug targets are 
localized either in the cell cytosol, for example heat shock proteins [80,81] and 
microtubules [82] or in the nucleus, i.e. DNA [83,84], and topoisomerases  [85,86]. 
Therefore, for an anticancer drug to exert its therapeutic effect it must sufficiently 
concentrate in the same intracellular compartment as its target. For this reason, it is 
crucial that this important variable not be overlooked, particularly in the early stages of 
drug screening.   
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Of all the intracellular drug localization phenomena associated with drugs due to 
their physicochemical characteristics, lysosomal sequestration of weak bases is one of the 
most prevalent. Many weakly basic molecules are excellent substrates for extensive 
sequestration in acidic lysosomes according to an ion trapping type of mechanism 
[4,87,88]. Christian de Duve, the Nobel laureate credited with discovering lysosomes, 
published a detailed theoretical analysis on ion trapping [8]. According to this work, 
substrates for ion trapping are typically weakly basic molecules with pKa values around 7 
that are membrane permeable in their unionized state and are relatively membrane 
impermeable when ionized [4,9,89]. Such molecules will exist to a significant extent in 
their membrane-permeable, free base form when they are present in the neutral cell 
cytosol. From the cytosol, the molecules can freely partition across all organelle lipid 
bilayers. When these molecules partition into organelles with very acidic internal 
environments (i.e., lysosomes, pH ~4-4.5), they are virtually 100% ionized. Unable to 
diffuse back out to the cytosol, the charged molecule remains trapped inside lysosomes. 
Normal cells typically have low lysosomal pH values around 4.0, and can theoretically 
concentrate up to 1000-fold higher concentration of drug compared to the cytosol [8,90].  
The extent of lysosomal sequestration of weakly basic drugs is a relevant 
therapeutic consideration, since in some instances lysosomal sequestration can account 
for nearly 100% of the total drug accumulation within a cell [7,89]. A diagrammatic 
representation of ion trapping is shown in Figure 1.2.  
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Figure 1.2. Mechanism of ion-trapping/pH partitioning in lysosomes. In the cytosol, 
which has a neutral pH, weak bases with pKa around 7 exist to a significant degree in the 
un-ionized, membrane permeable state. Upon crossing the lysosomal lipid bilayer, the 
acidic lysosomal pH (4-4.5) causes such weak bases to become predominantly ionized 
and membrane impermeable, therefore incapable of diffusing out. Weak bases are thus 
sequestered within lysosomes. 
 
Despite being relatively low, the concentration of drug in the cytosol is in pseudo-
equilibrium with concentrations in the lysosome. The theoretical lysosome-to-cytosol 
concentration ratio is dictated by both the pKa of the drug and the lysosome-to-cytosol 
pH gradient [8,87,88]. Under these circumstances small shifts in lysosomal pH can 
profoundly influence drug concentrations in the cytosol, where many drug targets are 
localized. This is not only important for the activity of drugs having cytosolic targets, but 
also for drugs having nuclear targets, since the nuclear envelope contains numerous pore 
complexes that allow for free diffusion of small, low-molecular weight molecules to and 
from the cytosol [91].  
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The maintenance of low pH in a subset of intracellular organelles, including 
lysosomes, is required for activation and functioning of lysosomal enzymes, and is 
necessary for cell growth and survival [92]. Lysosomal pH is maintained by several 
mechanisms, that balance the rate of proton pumping into organelles against proton 
leakage and counterion conductance [92]. Protons are pumped into lysosomes against a 
concentration gradient by the vacuolar-type ATPase (V-ATPase), a large multiple subunit 
enzyme consisting of two domains, a cytosolic V1 domain, and a membrane localized 
domain, V0 [93]. The activity of V-ATPase is regulated both intrinsically, by the 
association and dissociation of its V0 and V1 domains in response to signals such as 
glucose availability [93,94], and extrinsically by the build-up of a positive membrane 
potential due to the accumulation of protons, which inhibits further proton pumping [92].  
The V-ATPase has been shown to be efficient at maintaining low pH values in lysosomes 
despite the neutralization capacity of the accumulating bases, perhaps due to dissipation 
of the positive membrane potential, which allows lysosomes to continue to take up weak 
bases even after they accumulate to very high concentrations.  
While the lysosomal pH of normal cells is tightly regulated, as described above, 
we and others have shown that some cancer cell lines have defective acidification of 
lysosomes (18-21). Various studies have suggested a link between transformation and 
defective acidification of organelles in cancer cells. Jiang et al. demonstrated that 
transformation of human and murine cells with an H-ras oncogene resulted in elevation 
of lysosomal pH [95]. In other studies, the E5 oncoprotein found in the human 
papillomavirus was shown to interact with the 16-kDa proton pumping subunit of the V-
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ATPase and inhibit endosomal acidification [96]. Some tumor cell lines express V-
ATPases at their plasma  
Consistent with ion trapping theory, defective acidification of lysosomal pH in 
cancer cells should theoretically result in a reduced capacity for lysosomal sequestration 
relative to normal cells. Indeed quantitative evaluations carried out in our lab confirmed 
that cells with impaired lysosomal sequestration had reduced concentrations of the weak 
base tested in lysosomes relative to cells with normal, low lysosomal pH [88]. 
 
1.6. Intracellular drug distribution based (IDB) selectivity 
According to the ion trapping mechanism described previously, the low lysosomal 
pH of normal cells leads to extensive lysosomal sequestration of weakly basic drugs. 
Conversely, defective acidification of lysosomes in cancer cells results in a relatively 
reduced sequestration of weak bases in lysosomes. We propose that these differences in 
intracellular drug distribution between normal and cancer cells can be exploited to 
enhance selectivity of drugs with optimal physicochemical properties to cancer cells, 
essentially an intracellular distribution-based (IDB) drug targeting approach. The 
principle of the IDB targeting approach is that relative to normal cells with low lysosomal 
pH, reduced lysosomal sequestration of drugs in cancer cells with elevated lysosomal pH 
would allow a greater amount of the drug to interact with cytosolic and/or nuclear targets, 
thus enhancing activity. 
On the other hand, extensive sequestration in normal cells with low lysosomal pH 
would minimize drug-target interactions and therefore decrease the activity of the drug in 
normal cells, resulting in an overall enhancement of selectivity. A schematic of the 
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proposed IDB targeting approach is shown in Figure 1.3. The classical approaches to 
enhance selectivity of anticancer drugs discussed in the preceding section require the 
active drug to localize preferentially in or around cancer cells relative to normal cells, an 
approach which as discussed, has multiple limitations. In the IDB targeting approach, 
selectivity is achieved based on the fact that anticancer agents with optimized 
physicochemical properties can distribute differently in normal versus cancer cells, 
resulting in differences in drug-target interactions and ultimately, differences in drug 
response. Sequestration of the drug in lysosomes of normal cells, away from drug targets 
would reduce toxicity to normal tissues, thus increasing the maximum tolerated dose of a 
given weakly basic anticancer drug.  
We have preliminarily evaluated the aforementioned IDB drug targeting platform, 
using inhibitors of the molecular chaperone Hsp90, with or without lysosomotropic 
properties. Since Hsp90 inhibitors have cytosolic targets, their activity should be 
responsive to the degree of lysosomal sequestration, or lack thereof. We tested the 
inhibitors in vitro using cultured cells with low or elevated lysosome pH [22] and found 
that the lysosomotropic Hsp90 inhibitors were much more toxic (lower IC50) to cells with 
elevated lysosomal pH compared to cells with normal, low lysosomal pH. On the other 
hand, the non- lysosomotropic inhibitor GDA had no differential selectivity, regardless of 
the lysosomal pH status of cells.  
Quantitative evaluations of lysosome-to-cytosol concentration ratios of neutral 
and weakly basic inhibitors demonstrated that lysosome-to-cytosol concentration ratios 
for lysosomotropic inhibitors decreased in cells with elevated lysosomal (i.e., cancer-like 
cells). Alternatively, the lysosome-to-cytosol concentration ratio for the non-
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lysosomotropic GDA was low (near 1) and was not influenced by lysosomal pH. These 
evaluations are consistent with differences in intracellular distribution of lysosomotropic 
drugs due to differences in lysosomal pH having a significant impact on drug activity and 
selectivity in cells.  
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Figure 1.3. A diagrammatic overview of IDB selectivity. Drugs (represented as red 
dots) with lysosomotropic properties will be extensively sequestered in lysosomes of 
normal cells and will have relatively little interaction with cytosolic targets (top left cell). 
The same lysosomotropic drug in cancer cells with elevated lysosomal pH (top right cell) 
will have reduced lysosomal trapping and the concentration in the cytosol will 
concomitantly increase. The increase in cytosolic levels of the drug allows for greater 
interaction with targets and an increased therapeutic response in cancer cells relative to 
normal cells. Anticancer drugs without lysosomotropic properties will not differentially 
localize in normal and cancer cells regardless of lysosomal pH status (lower cells) and 
drug-to-drug target interactions will not be affected.   
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The preliminary evaluations discussed above indicate that differences in 
lysosomal pH between normal and cancer cells can have a profound influence on the 
differential intracellular distribution of weakly basic anticancer drugs in normal versus 
cancer cells, leading to profound differences in selectivity between the cell types. The 
objective of this thesis, therefore, is to evaluate the applicability of IDB selectivity to a 
broad spectrum of cancer cells, and whether optimizing physicochemical properties that 
influence lysosomotropism can further enhance IDB selectivity. A further objective is to 
determine whether lysosomal targeting of anticancer drugs concomitantly lowers 
systemic toxicity. The successful completion of this work will provide a basis for the 
rational design of anti-cancer agents with optimal physicochemical properties for 
selectivity, and hopefully provide impetus for researchers to explore intracellular 
targeting as a viable option to enhance selectivity. 
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Chapter 2: The prevalence and mechanism of defective acidification in cancer cells. 
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2.1. Introduction 
 
The IDB drug targeting approach that was introduced in Chapter 1 relies on 
differences in the intracellular distribution of weakly basic anticancer drugs in normal 
versus cancer cells to enhance selectivity. As discussed, these alterations in intracellular 
distribution of weakly basic drugs in normal versus cancer cells arise from differences in 
lysosomal-to-cytosol pH gradients that can exist between normal and cancer cells. While 
normal cells typically have a low lysosomal pH, some cancer cells have been shown to 
have defective lysosomal acidification [1,2,3,4], leading to differences in lysosome-to-
cytosol pH gradients between the cell types. In cancer cells with elevated lysosomal pH, 
the reduced lysosome-to-cytosol pH gradient reduces the degree of lysosomal trapping of 
weakly basic drugs. As a result, drug interaction with extralysosomal targets is enhanced 
in cancer cells relative to normal cells, leading to enhanced activity in cancer cells and 
providing an intracellular drug distribution based (IDB) selectivity. 
Since the changes in intracellular distribution of weak bases between normal and 
cancer cells rely on differences in lysosomal pH, the successful enhancement of 
selectivity through IDB targeting can only be achieved for cancer cells with defectively 
acidified lysosomes. Considering this significant limitation, it is important to establish the 
prevalence of defective acidification in cancer cells as well as to understand the 
mechanism leading to defective lysosomal acidification. In preliminary evaluations of 
IDB selectivity, our results showed that even small changes in lysosomal pH (~0.5 pH 
units) could significantly increase the IDB selectivity of a drug with optimal 
lysosomotropic properties [5]. Therefore, a major focus of the work described in this 
chapter was to develop a lysosome pH-determination assay that is highly sensitive to 
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small differences in lysosomal pH between normal and cancer cells in order to identify 
the extent to which the principles of IDB selectivity could potentially be applied.  
Although there are a number of reports of defective lysosomal acidification, it is 
not clear whether this phenomenon is typical of all cancer types, or whether it is a 
preserve of a few cancers. Defective lysosomal acidification has been reported for MCF-
7 (breast adenocarcinoma, [6]); CaCo-2 (colorectal adenocarcinoma [1]); HL-60 
(leukemia [3]) cancer cells, and in ras-transformed fibroblasts [2], which represent only a 
small fraction of cancer types. Thus far a systematic comparison of lysosomal pH 
between normal and cancer cells has not been carried out. Our studies aimed to evaluate 
lysosomal pH in normal and cancer cells to first of all define what constitutes a normal 
lysosomal pH, since a wide range of values have been reported in the literature. Based on 
this, we can determine the scope of cancer cells that will be candidates for IDB 
selectivity. 
It is important to understand the molecular mechanism underlying defective 
lysosomal acidification, first and foremost to ensure that this phenomenon is not 
artifactual, for example due to cell culturing conditions. Studies on defective lysosomal 
acidification to date have been inconclusive with regard to the mechanism and/or cause 
of defective acidification of cancer. While  some reports postulate that defective 
acidification may be a prerequisite for transformation [7], other reports suggest that 
defective acidification is a consequence of transformation [8].  
In other studies, metastatic cancer cells were shown to express V-ATPase at the 
plasma membrane [9], an unusual occurrence because V-ATPases are typically localized 
in endocytic organelles, where they function to acidify luminal pH. It is possible that 
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tumors growing in an acidic environment, which is caused by anaerobic respiration and 
build-up of lactic acid [10], may re-localize V-ATPases to the plasma membrane from 
endocytic organelles to maintain the neutral pH of the cytosol by extruding protons into 
the extracellular space. It has also been proposed that metastatic tumor cells purposefully 
recruit V-ATPases to the plasma membrane to acidify the extracellular environment so as 
to aid in metastasis and invasion [11]. Interestingly, in drug sensitive cancer cells 
characterized as having defective lysosomal acidification, lysosomal acidity is often 
restored in multi-drug resistant variants [4]. This scenario may contribute to drug 
resistance by enhancing the lysosomal sequestration of weakly basic anticancer drugs. 
In our investigations, we wanted to evaluate the influence of transformation on 
the lysosomal pH of a normal, primary cell. Primary cells, unlike established cell lines, 
are capable of limited cycles of cell division and are often obtained with limited passage 
numbers. If transformation has an effect on lysosomal pH, this would rule out the 
possibility that defective acidification is caused by artifactual factors unrelated to the 
process of a cell becoming a cancer cell. To investigate whether transformation 
influences lysosomal pH, we transformed RPTE cells with the simian vacuolating virus 
40 large T antigen (SV40 LT), which is a DNA tumor virus [12] well known to induce 
transformation of cells in vitro [13,14], and evaluated lysosomal pH before and after 
transformation. Since lysosomal acidification is known to be regulated primarily by the 
V-ATPase [15,16] we also evaluated the expression of V-ATPase subunit E1 in normal 
RPTE cells, and after transformation with SV40.  
While all the normal cells evaluated had a lysosomal pH centered around 4, the 
cancer cells exhibited a range of pH values, from values similar to that of normal cells, to 
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significantly elevated pH values. Many of the cell lines evaluated had lysosomal pH that 
would make them candidates for IDB selectivity (i.e., 0.5 pH units greater than lysosomal 
pH of normal cells). The transformation study showed that normal primary cells 
transformed with SV40-LT experience a disruption of lysosomal acidification, which is 
accompanied by changes in V-ATPase expression.  
These results ascertain that defective acidification occurs due to the process of 
transformation, and that the change in pH is mediated by the V-ATPase, as we might 
expect. In addition, we found that though not all cancer cells exhibit defective lysosomal 
acidification, a number of them have sufficiently elevated lysosomal pH to be candidates 
for IDB selectivity. 
 
2.2. Materials and Methods 
2.2.1. Cell culture 
  HL-60 cells were previously obtained from Dr Yueshang Zhang (formerly of 
Arizona Cancer Center), and were propagated in RPMI media to which 10% BCS, 
sodium bicarbonate, sodium pyruvate and HEPES buffer were added. Renal proximal 
tubule epithelial (RPTE) cells were obtained from Lonza USA, and were maintained in 
DMEM/F12 media supplemented with 10 ng/mL epidermal growth factor, insulin-
transferrin-selenium solution (Sigma) and 10% fetal bovine serum. Peripheral blood 
monocytes were isolated using density centrifugation. Briefly, 10 mL of venous blood 
was collected into an acid citrate dextrose tube by an experienced phlebotomist and 
immediately transported to the laboratory. The blood was mixed with 50 µL/mL of 
RosetteSep Human B cell enrichment cocktail (Stem Cell Technologies, Vancouver, 
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Canada), and incubated for 20 min at room temperature. The sample was diluted with an 
equal volume (10 mL) of PBS containing 2% FBS and mixed gently. It was then layered 
on 15mL of Ficoll-Paque density medium (Stem Cell Technologies, Vancouver, Canada) 
and centrifuged at 1200g for 20 min. The enriched B-cells were collected from the 
interphase between plasma and red blood cells. A pipette was used to draw out the 
plasma layer, and the B-cell fraction collected into a 15 mL centrifuge tube, washed twice 
with PBS + 2%FBS solution and incubated at 37°C, 5% CO2 incubator. All other cell 
lines were obtained from the American Type Culture Collection (Manassas, VA), and 
were maintained and propagated as recommended by the manufacturer.  
 
2.2.2. Anti-bodies and reagents 
Unless otherwise noted, reagents were obtained from Sigma (St. Louis, MO). 
Mouse anti-LAMP-1 was obtained from Developmental Studies Hybridoma (University 
of Iowa), mouse anti-SV40 LT from Santa Cruz Biotechnology (Santa Cruz, CA) and 
HRP-conjugated goat anti-mouse IgG from Sigma. Alexa Fluor 647 conjugated mouse 
IgG, Oreqon Green dextran (10,000MW) and lysine-fixable fluorescein dextran 
(10,000MW) were from Invitrogen (Carlsbad, CA).  
 
2.2.3 Immunofluorescence  
Coverslips were sterilized by rinsing with 90% ethanol, followed by exposure to 
UV light for 1 h, and then placed into the wells of a 6-well cell culture plate. Normal skin 
fibroblasts were seeded onto the coverslips in at a density of 2X10
5 
cells per well. Cells 
were allowed to adhere overnight, after which they were labeled with 1 mg/mL lysine-
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fixable fluorescein dextran for 2 h, followed by incubation in dextran-free media (chase) 
for various time periods (0, 3, 6, 9 hrs). At the end of the respective chase periods, cells 
were rinsed X2 with PBS, fixed with freshly made 4% paraformaldehyde in PBS and 
permeabilized with 0.05% saponin. Primary and secondary antibody solutions were made 
in 0.05% saponin and 10% FBS in PBS. Cells were labeled for 2 h with a 1:100 dilution 
of mouse anti-LAMP-1. Subsequent to incubation with primary antibody, the cells were 
rinsed x3 with PBS, followed by labeling for 1 h with a 1:1000 Alexa Fluor 647 
conjugated anti-mouse IgG. Cells were washed x3 with PBS, coverslips inverted onto a 
microscope slide and sealed with wax. Cells were imaged through the appropriate filter 
sets to visualize Oregon Green and Alexa Fluor 647 (fluorescein and Cy5 filters, 
respectively) mounted on a Nikon 80i epifluorescence microscope equipped with a 
Hamamatsu Orca ER digital camera. Images were processed using Metamorph software 
version 7 from Universal Imaging Corp (Downington, PA).  
 
2.2.4. Lysosomal pH assay 
A ratiometric fluorescence technique to determine lysosomal pH has been 
described previously [2,3,17], which we modified for lysosomal pH evaluations. The pH 
dependence of the Oregon Green spectrum was determined by dissolving 1µg/ mL of 
Oregon Green dextran into buffers of consisting of 150 mM NaCl, 20 mM Mes, 5 mM 
KCl, and 1 mM MgSO4, and adjusted to pH 4, 5, 6, 6.5 and 7, respectively using 1N 
NaOH. The fluorophore solution (500 µL) was pipetted into respective wells of an 8-well 
cell culture slide (Becton Dickinson, Franklin Lakes, NJ) and excitation spectra recorded 
from 425 to 510 nm wavelengths through a 525/10 nm band pass emission filter using a 
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microscope adapted Ratiomaster spectrofluorimeter (PTI, Trenton, NJ). The Ratiomaster 
spectrofluorimeter was equipped with a photomultiplier tube detector, Xenon excitation 
light source and monochromator to select excitation wavelengths. To evaluate the 
concentration dependence of the Oregon Green excitation spectrum, various amounts of 
the fluorophore were dissolved in pH 7 (composition described above) buffer to yield 
concentrations of 0.2, 0.4, 0.6 and 0.8 µg/mL and excitation spectra recorded as 
described.  
To determine lysosomal pH of cells, adherent cell types were plated at a density 
of 50,000 cells per well of an 8-well cell culture slide and allowed to adhere overnight. 
Cells were pulsed with 1 mg/mL Oregon Green dextran for 2 h, followed by a 6 h chase 
in dextran-free media. At the end of the chase period, the cells were washed with a buffer 
consisting of 150 mM NaCl, 20 mM Mes, 5 mM KCl, and 1 mM MgSO4, pH 7.4. 
Suspension cells were centrifuged after labeling, washed and resuspended in buffer to a 
final concentration of 5-10x10
6 
cells/mL. Twenty µL of cell suspension was pipetted onto 
a microscope slide and sealed with a coverslip prior to lysosomal pH determinations. The 
emission intensity ratio of Oregon Green excited at 495 and 450 nm was measured 
through a 525/10 nm band pass filter using a microscope adapted Ratiomaster 
spectrofluorimeter (PTI, Trenton, NJ), equipped with a photomultiplier tube detector, 
Xenon excitation source coupled to a monochromator to select excitation wavelengths. 
Emission wavelengths were selected through the use of a FITC filter. Due to the 
sensitivity of the PMT, it was necessary to protect samples from all ambient light (i.e., 
from computer monitors or overhead lights) by covering the microscope completely, in 
order to increase the signal/noise ratio. The ratios of Oregon Green emission (525 nm) 
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intensity at the two excitation-wavelength (495/450) ratios were calculated concurrently 
with the intensity measurements using the ratio function of the Felix software (PTI - 
Trenton, NJ). To create a calibration curve for pH determination cells were incubated in 
pH 4 - 7 buffers respectively containing the ionophores nigericin (10 μM) and monensin 
(20 μM), which equilibrate intracellular pH with buffer pH [10]. Curves were fit to a 
linear equation, which was used to determine lysosomal pH of the test cells.  
 
2.2.5. Expression of SV40-LT in RPTEC cells 
Expression of SV40-LT in RPTE cells was performed as previously described 
[14,18] A retroviral vector plasmid encoding the sequence for SV40 LT, 
pBABEpuroSV40LT (with ampicillin and puromycin selection markers) transformed into 
Escherichia coli, was obtained from the Addgene plasmid repository (Cambridge, MA) 
as a bacterial stab. Bacteria were plated on a Luria Bertani (LB) agar (10 g NaCl, 10 g 
peptone, 5 g yeast extract and 15 g agar) plate containing 100 µg/mL ampicillin. A single 
E.coli colony was picked out and grown in 5 mL broth containing 100 µg/mL ampicillin 
for approximately 16 h. When the OD600 of the bacterial suspension was between 0.2 and 
0.6, the 5 mL bacterial suspension was scaled up to 100 mL broth in an autoclaved 250 
mL Erlenmeyer tube, and grown a further 16 h. Plasmid DNA was extracted using the 
Wizard® Plus Midi Prep Kit (Promega, Madison, WI). Quantification and evaluation of 
purity was done using A260/A280 measurements using a Shimadzu BioMini 
spectrophotometer. SV40LT retroviruses were produced by co-transfecting the pBABE-
SV40LT plasmid with a replication incompetent packaging virus plasmid, pCL-Ampho 
(Imgenex, San Diego, CA) into HEK 293T cells. On the day before transfection of HEK 
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293T cells, 1x 10
6 
cells were plated in a 6 cm Costar cell culture plate (Fisher Scientific, 
Pittsburg, PA). DNA (1 µg SV40 + 1 µg pCL-Ampho) was transfected into the cells 
using the Fugene-6 transfection reagent (Roche, Indianapolis, IN), according to the 
manufacturer‘s instructions. Total DNA to Fugene-6 ratio was 2:6. The DNA complexes 
were maintained on the cells overnight, and 18 h post-transfection the media containing 
the DNA complexes was removed and replaced with fresh media (DMEM + 10% FBS). 
Twenty four hours later, the supernatant (containing retroviruses) was harvested from the 
HEK 293T cells, and the media replaced. A second harvest of viral particles was done 
after an additional 24 h. The two viral harvests were either stored at -80°C until use, or 
added to RPTE cells right after harvesting. RPTE cells to be infected with SV40 particles 
were plated the day prior to infection with viral particles to allow for adherence. On the 
day of infection, the media was removed from the RPTE cells and replaced with the viral 
supernatant harvested from HEK 293T cells, in the presence of hexadimethrine bromide 
(polybrene). The viral particles were incubated on the RPTE cells overnight. An 
additional overnight infection of RPTE cells was carried out with the second viral 
harvest, and the media changed to growth media. The RPTE cells were allowed to 
express the SV40 LT protein for 24 h, after which they were split into medium containing 
2 µg/mL puromycin for selection of transfected cells. The cells were maintained in 
puromycin until all control (non-transfected) cells died. Western blotting was then carried 
to evaluate expression of SV40 LT. The puromycin concentration with which to select 
efficiently transduced cells was determined by creating a kill curve whereby RPTE cells 
were passaged in various concentrations of puromycin ranging from 0 to 10 µg/mL. The 
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lowest concentration of puromycin that killed all control cells within 14 days was used to 
select transduced cells. 
 
2.2.6. Western blotting 
The expression of SV40LT in virally infected RPTE cells was evaluated using a 
western dot blot procedure, as described elsewhere [3]. To prepare cell lysates, one 75 
cm
2
 flask of RPTE cells, and one flask of RPTE cells transfected with SV40 (henceforth 
designated RPTE-SV40) were trypsinized, washed x3 with PBS and re-suspended in 1 
mL of a hypotonic buffer consisting of 15 mM potassium chloride, 1.5 mM magnesium 
acetate, 1 mM dithiothreitol, 10 mM Hepes (pH 7.4), to which 0.1 mM PMSF, 0.5 µg/mL 
DNAse and 1 µg each of aprotinin, leupeptin and pepstatin was added. Cell were allowed 
to swell on ice for 15 min, then homogenized with 20 strokes of a dounce homogenizer 
(pestle B). To the homogenate was added 0.2 mL of hypertonic buffer consisting of 375 
mM potassium chloride, 22.5 mM magnesium acetate, 220 mM Hepes (pH 7.4) and 1 
mM dithiothreitol. The lysate was vortexed briefly and centrifuged at 1000 x g on an 
Eppendorf benchtop microcentrifuge to pellet nuclei and cell debris. Ten µL of the 
resulting supernatant was pipetted onto a nitrocellulose membrane, which was directly 
placed into a blocking solution composed of 5% non-fat dry milk in tris-buffered saline 
(TBS), pH 7.4 + 1% tween (TBS-T). After blocking overnight, the membrane was 
washed with TBS-T and probed with mouse anti-SV40 primary antibody, followed by a 
goat-anti-mouse horseradish peroxidase-conjugated secondary antibody. The expression 
of V-ATPase subunit V1E1 in RPTE and RPTE-SV40 cells was evaluated by western 
blotting following SDS-PAGE. The protein concentration of cell lysates prepared as 
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outlined above was determined using the BCA assay. Twenty µg of protein was loaded 
and resolved on a 9% SDS-gel and transferred onto a 0.45 µm nitrocellulose membrane 
for 1 h at 100V. After blocking as described above, the membrane was probed with 
antibodies to SV40 and actin (control) followed by a goat-anti-mouse HRP-conjugated 
secondary. The protein dots or bands were detected with enhanced chemiluminescence 
(ECL) reagents, visualized by exposure to Kodak film.  
 
2.3. Results 
2.3.1. Time dependent localization of dextran in lysosomes 
In order to identify small changes in lysosomal pH between cell types, it was 
necessary to further optimize previously described approaches to measure lysosomal pH 
so as to develop an assay that was sensitive and reproducible. We first evaluated the 
minimum amount of time required for endocytosed fluorescent dextran to traverse the 
endocytic pathway and localize specifically in lysosomes. Previous protocols in our lab 
[3] and elsewhere [17] employed a 24 h chase period to localize dextran into terminal 
lysosomes. However, we have since shown that at 24 h, a significant portion of 
intracellular dextran was released into cell culture medium [19], which could reduce the 
of sensitivity the assay.  
The time dependent localization of fluorescent 10,000MW dextran in lysosomes 
was determined by evaluating the colocalization of dextran and lysosomes at various time 
points. To do this, we evaluated the time required for endocytosed dextran to co-localize 
specifically with the lysosome associated membrane protein-1 (LAMP-1), which is a well 
studied lysosomal marker [10]. After 3 h of chase, most of the endocytosed dextran was 
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localized in lysosomes (Figure 2.1); however, a significant portion of the endocytosed 
dextran was not completely colocalized with Lamp-1 positive compartments (lysosomes). 
In 6 h, the intracellular dextran was completely localized in lysosomes as indicated by the 
complete overlap of dextran with Lamp-1 (Figure 2.1). Therefore, in the subsequent 
lysosome pH determination experiments, we employed a 2 h pulse, and 6 h chase of 
dextran into lysosomes.  
 
3 h
Oregon Green 488
dextran
merge Lamp-1
 
Figure 2.1. Evaluation of intracellular localization of Oregon Green dextran with 
time. Merge of Oregon Green images (left panels) with Lamp-1 images (right panels) 
shows incomplete co-localization of dextran with Lamp-1 at 3 h (top middle panel), while 
at 6 h, dextran completely co-localizes with Lamp-1 (bottom middle panel). The area 
bounded by a solid in the merge panels represent a zoom-in of the area bounded by the 
dotted line.  
 
3 h 
 
6 h 
 
  
51 
  
2.3.2. Lysosome pH in normal and cancer cells 
Ratiometric pH probes typically have pH-dependent and pH-independent 
excitation or emission maxima. The principle of ratiometric fluorescence is that taking 
the ratio of these wavelengths should correct for factors such as the concentration of dye 
in the cells, or the degree of photobleaching, which should therefore give a more accurate 
estimate of organelle pH [20]. We therefore measured the pH and concentration 
dependence of the Oregon Green excitation spectrum in order to identify the pH 
dependent and independent wavelengths of the probe using our system, and to evaluate 
whether the emission ratio at these wavelengths was concentration dependent. As shown 
in Figure 2.2, the spectra revealed pH dependent peak at 495 nm. The second peak, at 460 
nm is expected to be pH independent, but showed a clear pH dependence (Figure 2.2). 
We therefore elected to use 450 nm as the pH independent excitation wavelength, since 
the dye emitted significantly at this wavelength, but the emission intensity did not change 
with pH. Contrary to expectation, the 495/450 nm ratio showed concentration 
dependence (Figure 2.3). This made it necessary to create calibration curves for each 
individual cell line evaluated, since different cell types may endocytose varying amounts 
of dextran which, given the concentration dependence of the ration, would influence the 
magnitude of the 495/450 nm ratio and result in inaccurate pH measurements. 
 Nevertheless, we were able to develop linear pH calibration curves that were 
reproducible. A representative pH calibration curve using Hs925.T skin cancer cells is 
shown in Figure 2.4. The inter-day variability in lysosomal pH of these cells using 
independent calibration curves was less than 10% (see Figure 2.4). Using this assay we 
evaluated lysosomal pH in a number of normal and cancer cells. Consistent with a 
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previous evaluation [21], all the normal cells evaluated in our study had lysosomal pH 
values around 4 (Figure 2.5). On the other hand, cancer cells exhibited an array of 
lysosomal pH values, ranging from 4 to 6.4. A significant portion of cancer cells had 
lysosomal pH values that were more than 0.5 pH units higher than in normal cells, which, 
according to theoretical calculations, indicates that they will be candidates for IDB 
selectivity. 
 
 
 
 
Figure 2.2. The pH dependent excitation spectrum of Oregon Green 488 dextran 
measured at 525 nm emission. 1µg/mL of dye was dissolved in buffers of different pH 
values (indicated by numbers) and spectra obtained as described in Materials and 
Methods. The spectra were overlaid using the Felix software.  
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Figure 2.3. The concentration dependent excitation spectrum of Oregon Green 488 
dextran measured at 525 nm emission. 0.2-1µg/mL of dextran was dissolved in pH 7 
buffer and spectra obtained as described in Materials and Methods. The spectra were 
overlaid using the Felix software. 
 
 
2.3.3 Expression of SV40 LT in RPTE cells 
 In an effort to establish the molecular basis of the defect in lysosomal 
acidification observed in some cancer cells, we were interested in evaluating whether 
transformation of cells normal RPTE cells would influence lysosomal pH regulation. 
Based on our finding that some cancer cells exhibited normal lysosomal pH regulation 
(see Figure 2.5), we hypothesized that upon transformation, cells may experience a 
disruption in lysosomal acidification, which may be normalized with continuous cell 
culture. If this is the case, then immediately after transformation, we should observe a 
significant increase in lysosomal pH that may dissipate with time. We therefore 
transformed normal primary RPTE cells with the SV40-large T antigen, which is a tumor 
oncoprotein that causes transformation by binding to p53 and retinoblastoma which are 
cell cycle regulators [23]. Attempts to transiently introduce SV40 into the primary cells 
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using lipid mediated delivery were unsuccessful. We therefore opted to use a retroviral 
vector to introduce SV40 into cells, as this approach allows for stable and efficient 
transduction of difficult-to-transfect primary cells [24]. The retroviral transduction was 
highly efficient, as evidenced by the observation that, while non-transduced cells were 
completely susceptible to puromycin within a few days, no cell death was observed in 
cells transduced with the retroviral vectors containing SV40LT and a puromycin 
resistance gene. The success of the procedure was further evaluated by performing a dot 
blot to detect SV40 expression in target RPTE cells. As shown in Figure 2.6, SV40 was 
successfully expressed in virally transduced RPTE-SV40, compared to control cells in 
which SV40 was not detected.  
 
2.3.4 Transformation influences expression of V-ATPase subunit E and lysosomal 
pH  
To determine the effect of transformation on lysosomal pH, we evaluated pH as 
described above in non-transformed and transformed RPTE cells.  We found that RPTE 
cells expressing SV40 had a significantly elevated lysosomal pH, compared to cells 
without SV40. We hypothesized that changes in lysosomal pH were most likely to be 
attributable to changes in V-ATPase expression levels, or changes in the activity of the 
enzyme. We therefore examined the expression of the V-ATPase subunit E1 in both cell 
types. The results showed that RPTE cells expressing SV40 LT had visibly reduced 
expression of the V-ATPase subunit E1 compared to control cells (see Figure 2.7). These 
results suggest that the modulation of lysosomal pH upon transformation is mediated by 
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V-ATPase activity, specifically through changes in V-ATPase expression that 
presumably lead to changes in lysosomal pH regulation and changes in lysosomal pH.  
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Figure 2.4. Representative lysosome pH calibration curve in Hs925.T skin cancer 
cells and interday variability assessment. Calibration curves were obtained by 
equilibrating the intracellular pH of Oregon Green-labeled cells with buffer pH using the 
ionophores nigericin and monensin. The ratio of Oregon green emission at 495 over 450 
nm was determined as described in Materials and Methods, and plotted against pH. Inter-
day variability in lysosomal pH determination was determined by measuring lysosome 
pH in these cells on 5 different days, and computing the means and standard deviation. 
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Figure 2.5. Lysosome pH in normal (black font) and cancer cell lines (red font) 
evaluated. Bars represent lysosomal pH ± s.d. (n=3) 
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Figure 2.6. Dot blot of SV40-LT expression in wild type and transformed RPTE 
cells. Cell lysates from normal and transformed cells were blotted onto a nitrocellulose 
membrane and probed with antibodies to SV40 LT, and an HRP-conjugated secondary 
antibody. Wild type RPTE cells completely lack the SV40LT protein, while virus 
mediated delivery of SV40LT into cells was successful in expressing SV40LT.  
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Figure 2.7. Expression levels of V-ATPase subunit E1 in wild type and transformed 
RPTE cells. The expression of V1E1 in transformed cells was significantly reduced in 
RPTE cells transformed with SV40-LT, which was accompanied by elevation in 
lysosomal pH.  
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2.4 Discussion 
In chapter 1, we introduced a novel anticancer drug targeting strategy that exploits 
a lysosomal defect associated with some cancer cells to enhance the selectivity of weakly 
basic anti-cancer drugs. As discussed, the IDB selectivity strategy is applicable only to 
cancer cells with defective acidification. The extracellular pH of solid tumors has been 
studied extensively, and methods to monitor the extracellular pH of tumors with precision 
are well characterized. However, few studies have been dedicated to characterizing the 
lysosomal pH of tumor cells. In Chapter 1, we proposed a novel approach to enhance the 
selectivity of drugs to cancer cells, based on optimizing intracellular drug distribution 
between normal and cancer cells, i.e., intracellular drug distribution-based (IDB) 
selectivity. Given that IDB selectivity is only applicable to cancer cells with defective 
lysosomal acidification, establishing the potential for broad applicability of this approach 
requires an understanding of the prevalence and mechanism of defective lysosomal 
acidification in cancer cells. 
Theoretical estimations show that perturbations in lysosomal pH as small as 0.5 
pH units can greatly influence the cytosolic concentration of weak bases in normal versus 
cancer cells according to the ion-trapping mechanism discussed in Chapter 1, thus 
influencing selectivity significantly. Therefore, in the interest of developing a lysosomal 
pH determination assay that was sensitive to such small pH differences between normal 
and cancer cells, a concerted effort was made to optimize the established lysosomal pH 
determination protocol so as to enhance sensitivity and reproducibility. In order to ensure 
our measurements captured the pH of lysosomes and not other endocytic organelles, we 
initially evaluated the time-course of localization of fluorescent dextran in lysosomes by 
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co-staining the endocytosed Oregon Green dextran pH probe with the lysosomal marker 
protein, Lamp-1. These evaluations also ensured that we selected the earliest possible 
time point at which the dextran was localized in lysosomes, to minimize loss of 
fluorescent dextran through release into media as this could reduce sensitivity. After 6 h 
of chase (incubation of cells in dextran free medium), the dextran was entirely co-
localized with Lamp-1, indicating that dextran was predominantly localized in lysosomes. 
Therefore in the pH determination assay, we employed a 2 h pulse (uptake of dextran into 
cells) and 6 h chase (incubation in dye-free medium to allow lysosomal localization). 
For our evaluations, we employed the ratiometric pH-dependent fluorophore 
Oregon-Green 488 which is a fluorinated derivative of FITC with improved 
photostability. In principle, ratiometric fluorophores such as Oregon Green should have 
dual excitation (or emission) maxima, one of which is pH dependent, the second pH 
independent. Taking the ratio of emission (or excitation) at these wavelengths should 
therefore enable pH measurements controlled for variables such as photobleaching and 
differences in dye loading between cell types. Oregon Green has dual-excitation emission 
peaks; a pH dependent peak at approximately 494 nm excitation and a pH-independent 
one at 460 nm [10]. We determined the dual excitation wavelengths of Oregon Green to 
be 495 and 460 nm (see Figure 2.2). The pH dependent spectrum showed that the 460 nm 
wavelength peak also had a pH dependent emission. We therefore opted to take a ratio of 
495 and 450 nm, since the latter wavelength showed minimal pH dependent emission. 
However, this ratio showed concentration dependence, which is contrary to expectation. 
It was therefore necessary to construct individual calibration curves for each cell line 
tested, and to keep pulse-chase and cell density conditions constant as much as possible. 
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While all the normal cells studied exhibited a low lysosomal pH between 4 and 
4.2, cancer cells exhibited a range of lysosomal pH values ranging from 4 to 6.4 (Figure 
2.5). Our lysosomal pH results for normal cells tend to be lower than has been reported in 
the literature, which may be due to the fact that previous such evaluations used 
fluorescein dextran as the pH probe [20,21]. Since fluorescein has a pKa of 6.8, it is most 
sensitive to pH around these values. In addition it lacks pH dependent fluorescence at pH 
values less than 5, creating a possibility that use of FITC-dextran to determine lysosomal 
pH overestimates the lysosomal pH. In comparison, Oregon Green dextran has a pKa of 
4.8 and shows pH dependent fluorescence intensity at pH values down to 3. It is therefore 
more ideal for pH measurements of very acidic lysosomes. As mentioned previously, we 
have found that IDB selectivity is enhanced significantly, even with modest differences 
in the lysosome pH between cell types. Therefore, the results of lysosomal pH in normal 
versus cancer cells suggest that a wide range of cancer cells may be candidates for IDB 
selectivity.  
It is interesting that although many cancer cells evaluated in our study tended to 
have elevated lysosomal pH compared to normal cells, a significant portion cancer cells 
maintained the same degree of lysosomal acidification as normal cells. These results 
indicate that a complex interplay of factors may responsible for the defective acidification 
phenomenon, such as the mechanism of transformation, or length and conditions of cell 
culture, and that these factors may influence diverse cell types differently. We speculate 
that cancer cells may initially show defective lysosomal pH under in vivo conditions, but 
under conditions of cell culture they may revert to having a normal lysosomal pH. Cancer 
cells in vivo typically grow in an anaerobic environment due to poor blood perfusion, 
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which results in low oxygenation. They therefore produce high levels of lactic acid into 
the cytosol [10]. In order for these cells to maintain the neutral cytosolic pH required for 
normal cell functioning, cancer cells may recruit V-ATPases to the cell membrane to 
extrude protons into the extracellular medium [10]. Indeed, reports have shown that V-
ATPases are expressed in the plasma membranes of some cells [10]. In conditions of 
cells culture, where cells are typically propagated in a monolayer, with plenty of access to 
oxygen, cells would no longer need to maintain V-ATPase expression at the plasma 
membrane, therefore, V-ATPase could re-localize to endocytic organelles. Our finding 
that MCF-7 cells maintained a lysosomal pH that was not significantly different from that 
of normal cells (Table 1), whereas, in a previous study, MCF-7 cells were reported to 
have significantly elevated lysosomal pH [6], may be explained by this hypothesis. This 
also lends credence to the possibility that extended cell culture may lead to a re-
distribution of V-ATPases to lysosomes and re-acidification of lysosomes. To 
conclusively answer this question, however, would require that the lysosomal pH of 
primary cells freshly isolated from a solid tumor be evaluated, and the effects of extended 
cell passaging on the pH evaluated. 
Evaluating the impact of transformation on lysosomal pH and pH regulation 
machinery of a normal, primary cell can provide information on the mechanism of 
defective acidification in the absence of confounding factors, such as length in culture. 
Additionally, such an approach can provide insights into the link between transformation 
and organelle acidification. To evaluate the role of transformation on lysosomal pH 
regulation, we transformed cells with the oncoprotein SV40LT, which effects cellular 
transformation by binding to p53 and the retinoblastoma cell cycle regulators [22]. Cells 
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transformed with SV40LT were found to have significantly elevated lysosomal pH (4.8 ± 
0.3) compared to control cells (3.9 ± 0.1). In addition, the cells had visibly reduced 
expression of the VIEI V-ATPase subunit, suggesting that the transformation process 
influences lysosomal acidification through disruption of lysosomal acidification 
machinery. Miura and co-workers have shown that the V1E1 subunit of V-ATPase 
interacts with the guanine nucleotide exchange factor mSos1, which is involved in 
growth factor-mediated cell growth control [23]. Based on their work, it appears as 
though V-ATPase itself plays a role in signaling processes that maintain normal cell 
growth. It therefore plausible that disruption of normal cell growth signaling during 
transformation may result in compensatory modulation of V-ATPase expression, perhaps 
an attempt by the cell to keep abnormal cell growth in check after transformation occurs. 
Interestingly, another group showed that mutations in the 16kDa subunit of the V-
ATPase that disrupted ATPase function caused cell transformation [7]. Based on this, the 
authors concluded that lysosomal de-acidification was a prerequisite for transformation. 
However, this could also support a conclusion that the observed lysosomal acidification 
defects are due to deficiencies in the cell growth regulatory pathway. It also suggests 
therefore, that defective acidification is not necessarily a prerequisite, but a consequence 
of transformation. 
It is unclear whether every type of cancer cell that expresses SV40LT will exhibit 
defective lysosomal acidification. However, our results provide a rationale for screening 
cancer cells that express SV40LT in order to logically identify cancer types that may 
have defective lysosomal acidification. In fact, SV40LT has been found to be expressed 
in a number of cancers [13,24,25]. A systematic study of lysosomal pH in these cell lines 
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would answer the question regarding whether IDB targeting strategy would be generally 
applicable to cancer cells that express SV40.  
In general, our results suggest that transformation influences lysosomal pH, an 
effect that is mediated by changes in the expression levels of V-ATPase. In addition, 
these results seem to suggest that cancer cells have defective lysosomal pH regulation 
immediately after transformation, an effect that may normalize over time. Further 
evaluations are required to provide definitive conclusions in this regard. With regard to 
IDB selectivity, our results suggest that although many cancer cells have normal 
lysosomal pH regulation, a number exhibit defective acidification that is adequate to 
enhance IDB selectivity. However, the scope of our lysosome pH evaluations was limited 
by the labor and time intensive approach to determine lysosomal pH. A high-throughput 
lysosome pH determination approach, as described by Liu et. al [26] may provide a better 
route to truly define the scope of defective lysosomal acidification in cancer cells and 
more readily define the extent to which IDB selectivity could be applicable to enhancing 
selectivity of anti-cancer drugs. 
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Chapter 3: The pKa of weakly basic anticancer agents correlates with the degree of 
intracellular drug distribution-based selectivity to cancer cells 
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3.1 Introduction 
The high degree of systemic toxicity caused by most anticancer drugs presents an 
extreme challenge to successful chemotherapy. In general, attempts to enhance the 
selectivity of anti-cancer drugs focus on enhancing the delivery of drugs to cancer cells, 
while attempting to reduce drug accumulation in normal cells. In Chapter 1, the classical 
approaches to enhance selectivity were discussed. These approaches share a common 
requirement in that the active drug is expected to accumulate to a greater extent in or 
around cancer cells, while avoiding normal cells. Though conceptually appealing, these 
approaches are seldom successful because in reality, it is extremely difficult to achieve 
truly site-specific delivery [1].  
An alternative approach to enhance anticancer drug selectivity focuses on 
intracellular drug distribution-based targeting, which would obviate the need for 
increased accumulation of drugs in or around cancer cells relative to normal cells. The 
general premise of this approach is that drugs with optimal physicochemical properties 
can distribute differently in normal versus cancer cells (i.e. in compartments that enhance 
drug-target interactions in cancer cells and in compartments that diminish drug target 
interactions in normal cells) thus enhancing selectivity to cancer cells. The mechanism of 
the IDB selectivity approach was discussed in detail in Chapter 1, and as discussed, is 
made possible by differences in the degree of lysosomal sequestration of weak bases 
between normal and cancer cells. Differences in lysosomal trapping arise due to 
differences in lysosome-to-cytosol pH gradients between normal and cancer cells which 
come about due to defective lysosomal acidification in some cancer cells.  
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In previous quantitative evaluations of the lysosome-to-cytosol concentration ratio 
of the weak base Hsp90 inhibitor 17-DMAG in cancer cells with defective lysosomal 
acidification (pH 6.5) and cancer cells with a lower lysosomal pH (5.1), we found that the 
lysosome-to-cytosol distribution ratio of the weak base 17-DMAG was much greater in 
cells with a low lysosomal pH, compared to cells with elevated lysosomal pH. The 
lysosome-to-cytosol concentration ratio of the non-lysosomotropic inhibitor, 
geldanamycin was not sensitive to differences in lysosomal pH and was close to one for 
both cell types. 
 According to the theoretical principles of ion trapping in lysosomes originally set 
forth by de Duve  [2], the lysosome-to-cytosol ratio of weakly basic drugs decreases with 
pKa, such that compounds with pKa less than 8 undergo progressively less lysosomal 
sequestration. We established this experimentally by quantitatively evaluating the 
lysosome-to-cytosol ratio of a series of aminoisoquinolines with pKa values ranging from 
4 to 9. [3]. We found that aminoisoquinolines with pKa less than 6 had lysosome-to-
cytosol concentration ratios close to 1, whereas those with pKa greater than 7 had 
significantly greater concentration ratios. Since both pH and pKa influence the lysosome 
versus cytosol weak base distribution, we postulated that pKa would likewise influence 
the IDB selectivity of weak bases in cells with differences in lysosomal pH values.  
To test this, we evaluated the selectivity of anticancer drugs with varying pKa on 
intracellular drug distribution-based drug selectivity, and whether compounds with 
optimal pKa for lysosomal sequestration would show the greatest selectivity. We chose to 
evaluate Hsp90 inhibitors, which are ideal model compounds for our evaluations, since 
Hsp90 is localized in the cytosol [4], therefore the activity of lysosomotropic Hsp90 
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inhibitors should be sensitive to the degree of lysosomal sequestration. The inhibitor 
geldanamycin (GDA) and its structural analogs were particularly well-suited for our 
evaluations since GDA is neutral and therefore non-lysosomotropic, yet is amenable to 
modification at the 17-position to create analogs with lysosomotropic properties. 
Importantly, modifications are possible at this position without an impact on Hsp90 
binding affinity. We therefore synthesized GDA analogs with pKa values ranging from 
5.8 to 12.4 for evaluation of IDB selectivity.  
In order to determine the contribution of intracellular drug distribution differences 
influence on selectivity, it is important that drugs tested bind to the target (Hsp90) with a 
similar affinity, since differences in binding affinity could potentially influence the 
apparent selectivity between analogs. Tian et al. studied the influence of structural 
modifications of GDA on Hsp90 binding affinity and showed that while some 
modifications do not affect Hsp90 binding, addition of bulky substituents to the 17-
position reduced affinity for Hsp90 [5]. For this reason, we evaluated the binding affinity 
of geldanamycin analogs to recombinant Hsp90 using a fluorescence polarization 
assay[6], which showed that the 17-position modifications did not have a significant 
impact on Hsp90 binding.   
The selectivity for each analog was assessed by comparing ratios of anti-
proliferative IC50 values in normal human fibroblasts versus human leukemic HL-60 
cells. In addition, similar selectivity assessments were performed in a cancer cell line 
with or without shRNA treatment against a subunit of the lysosomal V-ATPase that 
resulted in a corresponding cell line with a significant lysosomal pH elevation. When 
plotted against pKa, selectivity followed a bell-shaped profile with very low or very high 
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pKa analogs showing minimal selectivity. Optimal selectivity peaked for analogs with 
pKa values near 8. Additional selectivity evaluation of anti-cancer drugs with 
mechanisms of action distinct from that of Hsp90 inhibitors, with or without optimal 
lysosomotropic properties, supported these results, suggesting that the IDB selectivity 
platform would be applicable to a broad spectrum of anticancer cancer drugs, and not just 
to Hsp90 inhibitors.  
Collectively, these evaluations mark a significant advancement in understanding 
how weakly basic properties can be optimized to achieve maximum selectivity toward 
cancer cells with defective lysosomal acidification.  
 
3.2. Materials and Methods 
3.2.1. Synthesis of geldanamycin analogs 
Geldanamycin (GDA) analogs were synthesized in the laboratory of Dr. M. Laird 
Forrest. Synthetic procedures and NMR characterization of the GDA analogs can be 
found in Ndolo et al. [7]. 
 
3.2.2. Cell lines and cell culture reagents 
HL-60 cells were kindly provided previously by Dr Yueshang Zhang (formerly of 
Arizona Cancer Center) and were propagated in RPMI media to which 10% BCS, sodium 
bicarbonate (1.5 g/L), sodium pyruvate and HEPES buffer were added. Normal human 
fibroblasts (CRL-2076) and MDA MB 231 (HTB-26) human breast adenocarcinoma and 
HEK 293T cells were obtained from the American Type Culture Collection (ATCC), and 
were propagated in DMEM (GIBCO) containing 10% FBS (HyClone).  
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3.2.3. Determination of pKa values of geldanamycin analogs 
The ionization constants of geldanamycin analogs were determined by recording 
the pH dependent 
1
H-NMR chemical shift of methylene protons adjacent to the weakly 
basic amine of the GDA analogs, as described previously [8,9]. All NMR solvents and 
reagents were obtained from Cambridge Isotope Labs (Andover, MA) unless otherwise 
noted. Compounds were dissolved at a 1-3mg/ml concentration in D2O. pD 
measurements (henceforth denoted pH*) were carried out using a MiniLab model IQ125 
pH electrode calibrated with pH 7 and 4 or 10 standard NIST reference buffers (Fisher 
Scientific, Pittsburg, PA). pH* was adjusted using NaOD (40% in D2O) or DCl (20% in 
D2O). Typically, 0.2 -10 µL of acid or base was added to the sample in the NMR tube, 
tube shaken and 30 µL drawn to measure pH*. 1-H NMR spectra were recorded using a 
Bruker 400 spectrometer operating at a frequency of 400.13 MHz, and analyzed using the 
Bruker Topspin software. Water soluble 4-dimethyl-4-silapentane-1-sulfonic acid (DSS) 
was used as the reference peak. The sample probe was maintained at 37°C, and 64-256 
scans were collected per spectrum. pH* was converted to pH using the expression: pH = 
0.936pH* + 0.412 [10]. The chemical shifts of the appropriate protons at various pH 
values were recorded and plotted against pH, yielding sigmoidal plots that were fit to the 
sigmoidal, 4-parameter equation using SigmaPlot. The inflection point of the curves gave 
the pKa of the compound. 
 
3.2.4 Assessment of Hsp90 binding affinity of geldanamycin analogs 
The Hsp90 binding affinity of geldanamycin (GDA) in comparison to its 
derivatives was determined by measuring the competitive displacement of the Hsp90-
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bound fluorescent tracer GDA-FITC, by GDA and its analogs, using a fluorescence 
polarization assay previously described by Llauger-Bufi et al. [6]. Non-binding surface 
96-well plates (Corning) for high throughput fluorescence polarization were obtained 
from Fisher. GDA-FITC, obtained from BioMol (Enzo Life Sciences, Plymouth Meeting, 
PA ) was reconstituted in DMSO at a stock concentration of 10µM and further diluted to 
a final concentration of 10nM in an assay buffer consisting of 20mM Hepes, pH 7.3, 
50mM KCl, 5mM MgCl2, 20mM MgCl2, 20mM Na2MoO4, and 0.01% NP40. 0.1mg/ml 
bovine gamma globulin (BGG) and 1mM DTT was added to this buffer just prior to use. 
The final concentration per well of tracer was 2 nM. Recombinant Hsp90α (Enzo Life 
Sciences) was reconstituted in assay buffer to yield a final concentration of 40 nM per 
well. Control wells with buffer and GDA-FITC tracer only were included. Eight different 
concentrations of geldanamycin analogs ranging from 0-2000 nM were added, such that 
the final volume of protein, tracer and test compound was 100 µL. The plates were placed 
on a shaker in a 4°C refrigerator for 4 h, and fluorescence millipolarization (mP) units 
determined using a Wallac Envision Multilabel plate reader (Perkin Elmer). The tracer 
only mP values were subtracted from the test mP values, and converted to percent of 
control (wells devoid of drug) mP to arrive at the % inhibition per treatment. Curves were 
fit to 3 or 4 parameter logistic equations using SigmaPlot. The IC50 of inhibition was 
determined from the plots, and converted to Ki values using the equation below, 
developed by Nikolovska-Coleska et al.  [11] 
                                       Ki = [I]50/([L50]/Kd + P0/Kd+1) 
where, I50 denotes the concentration of the free inhibitor at 50% inhibition and is 
equivalent to the IC50, [L]50 is the concentration of free labeled ligand at 50% inhibition, 
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[P]0 is the concentration of protein at 0% inhibition and Kd is the dissociation constant of 
the protein-ligand complex. The Kd of GDA-FITC binding to Hsp90 was found to be 
33.4nM [6]. The equation is freely available at 
http//sw16.im.med.unich.edu/software/calc_ki/ and requires input of Kd of the 
fluorescent tracer and the IC50 only. The other relevant parameters in the equation have 
been previously determined by the authors, and need not be determined experimentally if 
the Ki calculator linked above is used. 
 
3.2.5 Knockdown of V-ATPase subunit V1E1 
 The lentiviral transfer vector pPGK-Neo-ATP6V1E1 encoding the target 
sequence 5‘-CAGATGTCTCCAATTTGATGAAT-3‘ against the V-ATPase V1E1 
subunit was obtained from Mission (Sigma, St. Loius, MO). For control cells, pPGK-Neo 
transfer vector contained the sequence 5‘-CAACAAGATGAAGAGCACCAA-3‘, which 
does not target any known mammalian gene. Lentiviral particles were produced by 
transfecting HEK293T cells with the transfer vector plus a lentiviral packaging mix 
according to manufacturer‘s instructions (Sigma). Typically, 5 X 10
5
 HEK293T cells 
were seeded in 10 cm dishes and allowed to adhere overnight. For transfection, 2.6 μg of 
vector DNA was combined with 26 µL of packaging mix and transfected into cells using 
Fugene-6 transfection reagent (Roche), as per manufacturer‘s instructions. DNA 
complexes were allowed to incubate on the cells overnight, and then media was replaced 
with growth media. The virus-containing cell culture supernatants were harvested after 
24h, media replenished, and a second harvest of virus particles done another 24h later. 
Prior to infection of target MDA MB 231 cells, the virus-containing media supernatant 
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was filtered through a 0.45-μm filter, and added onto 70% confluent 75cc flasks of MDA 
MB 231 cells, in the presence of 8 μg/ml hexadimethrine bromide. The viruses were 
allowed to infect the cells for 16-18h then media was replaced for a further 24h before 
analysis of knockdown was performed.  
 
3.2.6 Western blotting 
Cells in a 75-cc cell culture flask were trypsinized, washed X3 with PBS and 
resuspended in lysis buffer consisting of 1% NP-40, 50mM Tris and 150mM NaCl to 
which a protease inhibitor cocktail containing PMSF, aprotinin, leupeptin and pepstatin  
(Sigma, St Louis MO) was added. Protein concentration was determined using the BCA 
assay (Pierce, Rockford IL). 20 µg of protein was resolved on a 10% SDS gel and 
transferred onto nitrocellulose membrane for 1h at 100V. After transfer, western blot 
analysis of V1E1 and actin (loading control) was carried out using a goat polyclonal 
antibody to the V1E1 subunit (Santa Cruz Biotechnology) and a mouse monoclonal 
antibody to actin (Sigma). Anti-goat HRP conjugated secondary antibody was from Santa 
Cruz Biotech, and anti-mouse HRP from Sigma.  
 
3.2.7 Lysosome pH determination 
Lysosomal pH was determined following previously published protocols 
[12,13,14], with modifications. Briefly, 1x10
5
 cells/well were plated in 8-chamber tissue 
culture treated microscope slides (BD Falcon, Bedford, MA) and allowed to adhere 
overnight. Cells were incubated with 1mg/ml Oregon Green 488 dextran 10000MW 
(Invitrogen) for 2h, followed by a 6h incubation in dye-free medium to allow the dextran 
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to localize in lysosomes. At the end of the chase period, the 525/10 nm emission ratio of 
Oregon Green 488 at 495 and 450nm excitation wavelengths, respectively, was measured 
using a microscope adapted Ratiomaster spectrofluorimeter (PTI, Trenton, NJ), equipped 
with a photomultiplier tube detector. To generate a calibration curve for pH 
determination, buffers composed of 150mM NaCl, 20mM Mes, 5mM KCl, and 1mM 
MgSO4 were adjusted with 1N NaOH to pH 4, 5, 5.5, and 6 containing 10 μM nigericin 
and 20 μM monensin, were added to respective wells of the 8-chamber slide for 1 h to 
equilibrate intracellular pH with extracellular pH, and the 495/450 nm emission ratio 
measured as described [15,16], and as outlined in Chapter 2. A standard curve was 
obtained by plotting buffer pH against 495/450 nm emission ratio, which was linear 
between the pH range evaluated.  
 
3.2.8 Cytotoxicity assay 
Cell sensitivity to compounds was evaluated using the WST-1 (4-[3[(4-
iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate) assay 
(BioAssay Systems, Hayward, CA) which was performed according to the 
manufacturer‘s instructions. For adherent cells, 4000 cells were seeded per well of a 96-
well plate, and allowed to adhere overnight. Cells were incubated in increasing 
concentrations (9 different concentrations ranging from 0.00001 µm to 1000 µM) of drug 
for a period of 72 h. Suspension cells were added to wells at a fraction of the final 
volume, and drug added so that the final volume in each well was 100 µL. At the end of 
the drug treatment period, 10 µL of WST-1 solution was added per well, allowed to 
incubate at 37°C for 2 hours and absorbance at 450 and 620nm (reference) measured 
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using a Multiskan model MCC/340 microplate reader (ThermoElectron Corp). Cell 
viability as a percent of control (untreated) cell was plotted against drug concentration, 
and curves were fit to 3 or 4 parameter logistic Hill plot using SigmaPlot. The IC50 was 
determined from the curve fit.  
 
3.3 Results 
3.3.1 
1
H-NMR determination of geldanamycin analogue pKa 
In order to evaluate the role of pKa on IDB selectivity to cancer cells we required 
a series of anticancer agents with varying pKa values. It is important to evaluate drugs 
with the same molecular target and similar affinity for this target, since these factors can 
influence the apparent selectivity of the drug candidates. Geldanamycin is a neutral 
cytotoxic Hsp90 inhibitor which can readily be modified at the 17-position to create 
ionizable analogs. We therefore obtained GDA analogs in which the methoxy-group at 
the 17-position was replaced with various amine substituents, the structures of which are 
indicated in Table 1. The amine substituents were initially selected such that the 
calculated pKa of resultant analogs varied from around 5 to 12. To determine pKa values 
experimentally, we monitored the 
1
H-NMR chemical shift changes of protons adjacent to 
the basic ionizable group. Since our measurements were carried out in D2O solvents, a 
correction factor was necessary to convert pH-meter readings of inhibitor solutions in 
D2O (designated pH*) into pH. We used the equation by Krezel and Bal [10], obtained by 
establishing the correlation between pH-meter readings of various substances in H2O and 
D2O. Plots of chemical shift versus pKa yielded sigmoidal curves, an example of which is 
shown in Figure 3.1. The pKa values of GDA analogs were determined from these plots, 
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as described in Material and Methods, and ranged from 5.8 -12.4 (Table 1). An example 
of the overlaid spectra obtained for GDA analogs at different pH values in shown (Figure 
3.2), where the change in chemical shift of the protons as pH changes can readily be 
observed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. pH dependent chemical shift of protons adjacent to the amine group in 
the GDA analog with the substituent shown. Circles represent chemical shift (in D2O) 
of protons adjacent to the amine group (shown by arrows) at different pH values, with the 
sample probe set to 37°C. The data points were fit to a 3-parameter sigmoidal curve fit 
(solid line), and pKa was determined as the inflection point.  
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Figure 3.3 Competitive inhibition binding curve of GDA obtained using fluorescence 
polarization. Binding experiments were performed using 2 nM GDA-FITC as the tracer, 
under incubation with various concentrations of test compounds (circles). The data is an 
average of duplicate binding experiments, and were fit to a 4-parameter logistic equation 
(solid line). 
 
 
3.3.2. Assessment of Hs90 binding affinity of geldanamycin analogs  
Previous modifications to GDA showed that certain modifications to the 17-
position of geldanamycin have no impact on Hsp90, while bulky substituents seem to 
negatively impact binding [5]. We therefore evaluated the impact of derivatization on the 
binding of GDA analogs, in comparison to GDA. We utilized a fluorescence polarization 
competitive inhibition binding assay, which measures the competitive inhibition of 
binding of fluorescently labeled GDA (GDA-FITC) to recombinant Hsp90α by the test 
compounds. Using this assay, we evaluated the Hsp90 binding affinity of the synthesized 
GDA analogs in comparison to GDA.  
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Figure 3.4. Structures of GDA and GDA analogs evaluated, and summary of pKa 
and Hsp90 binding affinity.  Hsp90 binding data represent an average of n = 2. 
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Plots of fluorescence polarization (mP) values against log concentration of test 
compounds yielded sigmoidal curves, an example of which is shown in Figure 3.3. The 
IC50 of binding inhibition  was determined from these curves and converted to Ki as 
described in the methods section.  The Ki of GDA binding to Hsp90 was 117.8 nM, 
which is comparable to reported values using fluorescence polarization [17], while that of 
the analogs ranged from 33.7 to 250.3 nM. These results confirm that derivatization of 
GDA to create analogs with variable pKa had no significant impact on Hsp90 binding 
affinity (see Figure 3.4) 
  
3.3.3. Selectivity assessment of geldanamycin analogs in normal versus cancer cells 
In our previous work, we showed that changes in the intracellular distribution of 
weakly basic drugs in cells with low lysosomal pH versus cells with elevated lysosomal 
pH resulted in enhanced selectivity of lysosomotropic Hsp90 inhibitors to cells with 
elevated lysosomal pH [18]. In the present work, we sought to identify the optimal pKa 
for intracellular distribution based selectivity to cancer cells. We evaluated the selectivity 
of Hsp90 inhibitors with variable pKa values in HL60 human leukemic cancer cells, 
which, at the time of these experiments, was determined to have a lysosomal pH of 5.6, in 
comparison to normal human skin fibroblasts, which were previously determined to have 
a lysosomal pH of 4.2 [14] .Selectivity was defined as the ratio of the IC50 of a given 
inhibitor in normal cells divided by the IC50 in HL60 cells. Accordingly, ratios close to or 
equal to one indicate similar or equal activity of a given drug in both normal and cancer 
cell lines, and therefore little or no selectivity towards cancer cells. We determined the 
selectivity for each analog and plotted the results against pKa of each inhibitor. Plots of 
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selectivity versus pKa yielded a bell shaped curve, with maximum selectivity observed 
for inhibitors with pKa around 8. Inhibitors with pKa less than 7, and greater than 9 had 
little selectivity to cancer cells. The neutral inhibitor GDA showed a minimal degree of 
selectivity toward HL60 cells (ratio ~ 2) which is consistent with the fact that, being a 
non-lysosomotropic compound, it is not subject to changes in intracellular distribution in 
response to lysosomal pH. 
In an effort to rationally explain the selectivity profile observed for normal versus 
cancer cells as a function of pKa we examined the theoretical distribution of weak bases 
in lysosomes as a function of pKa. The mechanistic basis for lysosomal sequestration of 
weak bases via ion trapping was reviewed in detail by deDuve and co-workers [2]. From 
this work, we derived the equation to determine the ratio of drug concentration in 
lysosomes to that in the cytosol at steady state as: 
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whereby, Ka denotes the weak base acid dissociation constant, [H+] is the proton 
concentration (subscript c represents cytosolic, l represents lysosomal), while α denotes 
the ratio of permeability of the un-ionized versus the ionized form of the weak base 
through the lysosomal lipid bilayer. This term was previously measured experimentally 
for the compound 17-DMAG [19], and was determined to be 0.001. We assumed that for 
structurally similar compounds, the α-value would be relatively constant. We therefore 
used this α-value in our calculation, since the GDA analogs used in our study are 
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structurally similar to 17-DMAG. The lysosomal and cytosolic pH entered was pH 4.2 
and 7.4 respectively, which is typical of normal cells. Using these parameters, we 
calculated the theoretical concentration ratio in the lysosomes versus cytosol of weak 
bases with pKa values ranging from 4 to 12.4. Plotting these ratios against pKa resulted 
in a bell shaped curve, whereby the maximum degree of lysosomal sequestration 
occurred with compounds of pKa around 8, as shown in the insets of Figures 3.5 and 3.6 
for comparison with selectivity data. The theoretically determined weak base distribution 
profile indicates that compounds with pKa approaching 8 will undergo the greatest 
degree of lysosomal sequestration in cells with normal, low lysosomal pH and should 
therefore have the least activity in normal cells.  Assuming that steady state accumulation 
of drug is achieved in both cell types, and that the total cellular drug concentration in 
normal and cancer cells is the same, the theoretical calculation predicts a 22-fold 
difference in cytosolic concentrations of weak bases with pKa 8 between cancer cells 
with lysosomal pH 5.6 compared to normal cells with pH 4.4. Therefore, taken together, 
the theoretical evaluations and the experimental results provide strong support for the role 
of intracellular drug distribution on the selectivity profile as a function of pKa observed 
in cancer versus normal cells observed. 
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Figure 3.5 Selectivity assessment of Hsp90 inhibitors in HL60 cancer cells compared 
to normal human fibroblasts. Selectivity of the weakly basic  drugs peaked with 
inhibitors having a pKa of 8. GDA was minimally selective consistent with its lack of 
lysosomotropic properties. Bars represent the ratio of IC50 of inhibitors in cancer cells 
over IC50 in normal cells. Inset: The theoretical lysososome:cytosol concentration ratio of 
weak bases as a function of pKa. 
 
 
3.3.4 Selectivity assessment of geldanamycin analogs in cancer cells with low or 
elevated lysosomal pH 
As discussed above, theoretical assessments predict that compounds with pKa 
around 8 are predicted to undergo the greatest degree of lysosomal sequestration. 
Therefore the selectivity profile observed for Hsp90 inhibitors as a function of pKa 
appears to support the notion that compounds with optimal lysosomotropic properties 
 will have an optimal degree of IDB selectivity. However, cancer drugs typically have 
intrinsic selectivity towards cancer cells due to biochemical/metabolic differences [19], 
that are unrelated to intracellular drug distribution. It could also be argued that the 
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increased activity of the Hsp90 inhibitors in cancer cells relative to normal cells can be 
attributed to differences in the expression of drug transporters in the two cell types, which 
could influence the relative intracellular drug concentrations.   
Therefore, to establish the unambiguous contribution of IDB targeting to the 
observed selectivity would require evaluation of selectivity in a pair of cell lines that 
differ only in lysosomal pH, but are otherwise identical. Although, many cancer cell lines 
have been shown to have defective acidification of lysosomes, we found that a number of 
cancer cell lines maintain normally acidified lysosomes (see Chapter 2, section 3.1). An 
example is the MDA MB 231 breast adenocarcinoma cell line, which maintains a 
lysosomal pH around 4.2, similar to the lysosomal pH of most normal cells. We therefore 
evaluated selectivity in this cell line, in comparison to the same cell line manipulated 
using molecular biology techniques to have defective lysosomal acidification.  
Lysosomal acidification is controlled by the activity of V-ATPase, which is a 
membrane anchored proton transporter that pumps protons into the lumen of the 
lysosomes against a concentration gradient to lower luminal pH [19]. Lu et al. have 
previously showed that knocking down a subunit V0c of V-ATPase, resulted in impaired 
V-ATPase activity without otherwise influencing cell growth [20]. Although the authors 
did not establish the impact of this manipulation on lysosomal pH, we reasoned that it 
would impair the proper functioning of V-ATPase, and result in defective lysosomal 
acidification, given that proton-pumping by V-ATPase is one of the primary mechanisms 
for the acidification of lysosomes [21]. Therefore to create an MDA MB 231 cell line 
with elevated lysosomal pH, we targeted the V1E1 subunit of V-ATPase for knockdown 
using lentiviral vector shRNA. The lentiviral-mediated transfer was chosen since this 
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approach allows efficient, high throughput and stable knockdown of target proteins [19]. 
MDA MB 231 cells that were to retain low lysosomal pH were incubated with lentiviral 
particles containing non-target sequence shRNA that should have no effect on V-ATPase 
expression and therefore have no influence on lysosomal pH.  This approach controls for 
any non-specific effects of lentiviral infection, if present. Knockdown of the V-ATPase 
subunit was confirmed by western blotting, which showed a significant reduction in 
V1E1 expression in cells treated with V1E1 shRNA relative to control (Figure 3.6). 
Importantly, knockdown of lysosomal pH using this approach had no discernible effect 
on the growth of cells (Figure 3.7). Evaluation of lysosomal pH after subunit knockdown 
showed that lysosomal pH was significantly elevated to pH 5.6. We subsequently 
evaluated the IC50 of Hsp90 inhibitors in both cell types and calculated selectivity as IC50 
in MDA MB 231 cells with low lysosomal pH divided by IC50 in MDA MB 231 cells 
with elevated lysosomal pH. Similar to the previous results, selectivity in this pair of cell 
lines peaked with compounds of pKa around 8 (Figure 3.8). Inhibitors with pKa greater 
than 9 or less than 7 had minimal or no selectivity towards cells with elevated lysosomal 
pH. The non-lysosomotropic Hsp90 inhibitor GDA showed no difference in activity in 
cells with high or low lysosomal pH, therefore no IDB selectivity. This is consistent with 
our hypothesis, and provides support to the conclusion that the differences in activity of 
Hsp90 inhibitors did not arise from the procedure employed to elevate lysosomal pH or 
the elevated lysosomal pH status itself, but due to a difference in drug distribution of 
inhibitors in low versus elevated lysosomal pH cells. 
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Figure 3.6. Western blot assessment of VIEI expression in MDA MB 231 cells. 
Compared to wild type MDA-MB 231 cells, scrambled shRNA had no effect of V1E1 
expression, and lysosomal pH. V1E1 shRNA reduced expression of the V-ATPase 
subunit, resulting in elevated lysosomal pH. 
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Figure 3.7. Growth curves of MDA-MB 231 cells (untreated) over the time course of 
cytotoxicity evaluation (72h) ○ wild type,▼V1E1 silenced. No significant difference 
was observed between growth rates of wild type and shRNA cells. 
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An interesting observation is that the selectivity obtained using identical cells 
varying only in lysosomal pH was much greater, and the shape of the IDB selectivity-
pKa curve was different from that observed between normal fibroblasts and HL-60 
cancer cells. Several factors could account for this. First, it is possible that the cells lines 
vary in the degree of uptake of Hsp90 inhibitors. The plasma membrane permeability, 
number of lysosomes as well as lysosome membrane permeability between the cells types 
may differ, thus influence the lysosome-to-cytosol distribution. Drug transporters may 
also be differentially expressed between the cells lines. Reduced drug uptake in HL-60 
cells would reduce the apparent IDB selectivity. Therefore, the ideal model to determine 
the influence of intracellular drug distribution differences on selectivity is one of two 
identical cell types differing only in lysosomal pH, since both cell types would be 
similarly influenced by variables that impact drug uptake and distribution. 
 3.3.5. Selectivity assessment of other classes of anti-cancer drugs  
In the previous studies we employed a series of Hsp90 inhibitors with variable 
pKa values to determine the optimal pKa for selectivity enhancement through IDB 
targeting. Our results showed that inhibitors with pKa around 8 will have the greatest 
enhancement of IDB selectivity. However, to establish the general applicability of the 
IDB targeting approach to enhancing the selectivity of anti-cancer drugs, we additionally 
tested drugs with mechanisms of action distinct from the Hsp90 inhibitors, with and 
without lysosomotropic properties. Mitoxantrone (MTX) and daunorubicin are DNA 
alkylating drugs with pKa values of 8 and 8.1, respectively [22]. Accordingly, based on 
our hypothesis and previous results, they should be selective to cells with elevated 
lysosomal pH.  
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Figure 3.8. Selectivity assessment of Hsp90 inhibitors in MDA-MB 231 cells with 
lysosomal pH 4.2 versus shRNA treated MDA-MB 231  with lysosomal pH 5.6 
Selectivity follows a bell shaped curve with maximum selectivity of inhibitors observed  
for compounds with  pKa ~ 8. GDA was not selective to cells with elevated lysosomal 
pH, consistent with its lack of lysosomotropic properties. Bars represent the ratio of IC50 
of inhibitors cells with lysosomal pH 4.2 over IC50 in cells with lysosomal pH 5.6. Inset: 
The theoretical lysososome:cytosol concentration ratio of weak bases as a function of 
pKa. 
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Figure 3.9. Selectivity assessments of weakly acidic and weakly basic anti-cancer 
drugs distinct from Hsp90 inhibitors. Selectivity was determined in MDA-MB 231 
cells with lysosomal pH 4.2 versus shRNA treated MDA-MB 231 with lysosomal pH 5.6. 
Bars represent the ratio of IC50 of inhibitors in cells with normal lysosomal pH over IC50 
of cells with elevated lysosomal pH. **, p < 0.05; *, p>0.05  
 
 
 
In accordance with the IDB targeting approach, weakly acidic compounds, which 
are not substrates for lysosomal trapping, are not expected to show selectivity irrespective 
of the degree of lysosomal sequestration. To evaluate this we tested the selectivity of the 
weakly acidic compounds 5-fluorouracil (5-FU) and chlorambucil (CBL).  5-FU has a 
pKa 8 [23], while chlorambucil has a pKa of 5.6 [24]. GDA was included as a control; 
since it is neutral, and we have shown that its activity in cells is insensitive to changes in 
lysosomal pH. In agreement with the hypothesis, the weakly basic drugs had statistically 
significantly enhanced selectivity to cells with elevated lysosomal pH, while the weakly 
acidic drugs 5-FU and CBL had no selectivity to cells with elevated lysosomal pH 
(Figure 3.9), similar to the control compound GDA.  
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3.4. Discussion 
 The intracellular distribution of drugs is seldom considered in the design of drugs 
with optimal activity, yet it is a fundamentally important variable in drug activity, since 
drugs must localize in the vicinity of their target in order to achieve their therapeutic 
effect. Weakly basic drugs are known to extensively accumulate in acidic lysosomes 
[25,26], which can greatly influence their interaction with extra-lysosomal drug targets 
and influence activity. Normal cells typically have acidic lysosomes, in which the low pH 
is maintained by the activity of the V-ATPase enzyme, which pumps protons into the 
lumen of lysosomes against a concentration gradient. The cytosol typically has a pH close 
to neutral, creating a lysosome-to-cytosol pH gradient that drives the accumulation of 
weak bases into lysosomes.  However, defective acidification in some cancer cells 
reduces their capacity for lysosomal sequestration of weakly basic drugs, thus increasing 
the amount of drug available to interact with extralysosomal targets in cancer cells 
relative to normal cells. We hypothesize that these differences in intracellular distribution 
of weak bases between normal and cancer cells can be exploited to enhance selectivity to 
cancer cells.    
In support of this hypothesis, we showed that weakly basic drugs were 
significantly less toxic to cells with low lysosomal pH, compared to cells with elevated 
lysosomal pH [19]. This intracellular drug distribution-based (IDB) targeting approach to 
enhance the selectivity of anticancer drugs represents a paradigm shift from classical 
approaches to enhance selectivity, which require that the active anti-cancer agent be 
directly targeted to the vicinity of cancer cells while avoiding normal cells. Such ‗magic 
bullet‘ targeting approaches have showed some promise, but not a great deal of success  
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particularly due to the difficulty of achieving site-specific localization [1]. The IDB 
approach obviates the necessity for tumor specific localization of the drug, since the drug 
accumulates to the same extent in both cancer and normal cells, but differences in 
intracellular distribution provide selectivity. 
In the work outlined in this chapter, we tested whether the IDB targeting approach 
could be optimized according to the pKa of the weak base. To carry out our evaluations, 
we selected Hsp90 inhibitors as model compounds, since their target – Hsp90 – is 
localized in the cytosol [19] therefore their activity should be influenced by the degree of 
lysosomal sequestration. The inhibitor geldanamycin (GDA) and its structural analogs 
were particularly well-suited for our evaluations since GDA is neutral and therefore non 
lysosomotropic, yet is amenable to modification at the 17-position to create analogs with 
lysosomotropic properties. We therefore synthesized Hsp90 inhibitors with pKa ranging 
from 5.8-12.4 (Figure 3.3) for the selectivity evaluations. The target binding affinity of 
the compounds is an important factor to establish, since the binding affinity could 
influence the apparent selectivity between compounds. We therefore carried out 
competitive Hsp90 binding affinity experiments using a fluorescence polarization assay 
that confirmed that these modifications had no significant impact on Hsp90 binding 
affinity (see Figure 3.3).  
Selectivity was determined as the ratio of anti-proliferative IC50 in normal cells 
versus cancer cells. Accordingly, ratios close to one indicate little or no selectivity, while 
ratios greater than one indicate a degree of selectivity. Selectivity plotted against the pKa 
values of the weakly basic compounds, followed a bell-shaped profile, with maximum 
selectivity occurring for compounds with pKa values around 8. GDA, which is neutral 
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and not lysosomotropic, was minimally selective to cancer cells. To establish a rational 
explanation for the observed selectivity profile, we evaluated the lysosome-to-cytosol 
distribution of weak bases. de Duve and co-workers, published the kinetic principles of 
ion trapping [2]. Based on these principles, we derived equation 1, from which we 
determined the steady state ratio of a weakly basic drug in lysosomes versus cytosol as a 
function of pKa. We assumed a lysosomal pH of 4.2, and a cytosolic pH of 7.4, both of 
which are typical of normal cells. For cancer cells, we used a lysosomal pH of 5.6, which 
was the lysosomal pH determined for the HL60 cells used in this study. Compounds with 
pKa 8 underwent the greatest degree of lysosomal sequestration in both normal and 
cancer cells. These results are consistent with similar theoretical simulations published by 
Trapp et al., and show that compounds with pKa 8 will have the most extensive 
sequestration in lysosomes of normal cells, therefore the least activity in normal cells 
resulting in a high selectivity to cancer cells. The observed selectivity profile is therefore 
consistent with the differences in intracellular distribution in cells with normal versus 
elevated lysosomal pH. 
The selectivity results obtained in normal versus cancer cells are consistent with 
our hypothesis based on the theoretically determined intracellular distribution profile of 
weak bases. However, anticancer drugs typically have intrinsic selectivity to cancer cells 
unrelated to their intracellular distribution, due to factors such as metabolic/biochemical 
differences between the cell types [27]. For this reason, to explicitly determine the role of 
pKa-influenced intracellular drug distribution on selectivity, we also evaluated selectivity 
in a pair of cancer cell lines that were otherwise identical, but differed in lysosomal pH. 
In our evaluations of lysosomal pH outlined in Chapter 2, we found that some cancer 
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cells maintain a normal lysosomal pH, an example being the MDA-MB-231 cell line. We 
reasoned that disrupting lysosomal acidification in this cell line using a genetic 
engineering approach would create a corresponding cell line with defective lysosomal 
acidification. It is well established that the key regulator of lysosomal pH is the V-
ATPase enzyme, which pumps protons into lysosomes against a concentration gradient 
[21]. Lu and co-workers have shown that targeting the V-ATPase for knockdown in 
highly metastatic human hepatocellular carcinoma cells reduced the metastatic potential 
of the tumors, presumably due to a disruption of the proton pumping activity of the V-
ATPase  [19]. We hypothesized that targeting the V-ATPase subunit in MDA MB 231 
cancer cells would likewise disrupt the pumping of protons into lysosomes in this cell 
line resulting in elevation of lysosomal pH.   Using the lysosomal pH determination assay 
described in Chapter 2, we confirmed that knockdown of the VIEI subunit of V-ATPase 
in MDA MB 231 cells resulted in elevation of lysosomal pH. This procedure had no 
discernible effect on the growth of the cells and provided an appropriate model with 
which to test the influence of pKa on intracellular distribution and selectivity.  
Selectivity evaluations in this pair of cell lines were consistent with the selectivity 
profile observed in cancer versus normal cells.  As before, maximum selectivity was 
observed for weak base pKa values around 8, while selectivity tapered for inhibitors with 
pKa values greater than or less than 8. However, the shape of the bell shape curve was 
different in the normal/cancer selectivity evaluation compared to the evaluation in 
identical cell lines with varying lysosomal pH. This may be due to the fact that normal 
cells may differ from cancer cells in the intracellular drug concentration and time to reach 
steady state both of which are influenced by membrane permeability. Nevertheless the 
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similarity in shape of the selectivity profile of the two selectivity evaluations, and the fact 
that both evaluations identified weak bases with pKa 8, which undergo the greatest 
degree of lysosomal sequestration as having optimal selectivity point to intracellular drug 
distribution differences in the observed selectivity. GDA did not show selectivity, as 
expected since it is not a substrate for lysosomal trapping. The lack of sensitivity of GDA 
to the changes in lysosomal pH also provide an appropriate control against the possibility 
that the knockdown of V-ATPase through virus mediated shRNA delivery sensitizes cells 
to drug treatments through mechanisms unrelated to the impact of knockdown on 
lysosomal pH and the corresponding change in drug distribution. 
 To establish the applicability of the IDB targeting approach towards enhancing 
the selectivity of a wide spectrum of anticancer drugs, we broadened our selectivity 
evaluations to include additional classes of anticancer drugs. Two weakly basic drugs 
with optimal pKa for selectivity, and two weakly acidic drugs were selected. GDA was 
employed as a control, since we have shown that its selectivity is not influenced by 
changes in lysosomal pH. The weakly basic drugs, mitoxantrone and daunorubicin have 
pKa values of 8.1 [19] and 8 [19], respectively. The anti-metabolite 5-FU has a pKa of 
8.2 [23], while chlorambucil has a pKa of 5.8 [24]. All of these drugs have DNA as their 
target, therefore differences in lysosome-to-cytosol concentrations between cells with low 
versus elevated lysosomal pH, or lack thereof, should influence selectivity (or for acidic 
drugs, show no difference in selectivity). Consistent with the previous results, both 
weakly basic drugs were significantly more selective to cells with elevated lysosomal pH 
compared to the control (GDA). Interestingly, despite having close to the same pKa as 
DNR, MTX had a much lower selectivity enhancement in comparison to DNR. This may 
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be attributed to the fact that biotransformation of MTX has been shown to involve 
oxidative enzymatic intramolecular cyclization of the phenelenediamine structure, which 
would result in a product with a much reduced pKa. In this form, the compound would no 
longer be an ideal lysosomotropic compound, which would lower its selectivity on the 
basis of intracellular distribution.  In addition, the lysosome-to-cytosol distribution ratio, 
which is influenced by other factors besides pKa (such as the permeability ratio of the 
ionized versus the unionized species), may be lower for MTX than DNR. As expected, 
the weakly acidic drugs were not selective to cells with elevated lysosomal pH, and were 
not different from the GDA control. 
It is clear that the physicochemical properties of drugs can have profound effects 
on drug distribution and activity. The current results illustrate that optimizing the 
physicochemical properties of lysosomotropic anti-cancer drugs can result in compounds 
with optimal selectivity to cancer cells with defective lysosomal acidification.  These 
results provide additional support for the feasibility of the IDB selectivity approach, and 
provide a rationale for identifying physicochemical properties of compounds that can 
maximize IDB selectivity. 
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Chapter 4: The role of lysosomes in limiting drug toxicity in vivo
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4.1. Introduction 
In Chapter 1, the intracellular drug distribution based (IDB) targeting approach to 
enhance the selectivity of drugs to cancer cells was introduced and discussed in detail. 
Evaluation of the IDB targeting strategy in vitro, using cultured cells, showed that drugs 
with lysosomotropic properties were significantly more selective to cells with elevated 
lysosomal pH [1]. These studies suggest that design or modifications of cancer drugs to 
impart lysosomotropic properties should be beneficial in promoting IDB drug selectivity. 
Furthermore, evaluation of lysosomal pH in a variety of cancer cells showed that many 
cancer cells were characterized by elevation in lysosomal pH, therefore IDB selectivity 
would be applicable to a variety of cancer types.  
However, a significant concern remains regarding whether or not purposefully 
targeting toxic anticancer agents to lysosomes imparts a degree of safety in vivo. In the 
current study, we specifically tested whether sequestration of anticancer drugs in 
lysosomes can reduce drug-induced toxicity in vivo. Our hypothesis predicts that control 
mice (normal lysosomal pH) will have a high degree of lysosomal sequestration of a 
lysosomotropic drug, thus limiting the interaction of extra-lysosomal targets with the 
drug. This model also predicts that in experimental mice (with elevated lysosomal pH), 
lysosomal sequestration will be reduced, thus increasing drug-target interactions and 
toxicity.  
We therefore evaluated this drug selectivity platform in vivo using Hsp90 
inhibitors with or without lysosomotropic properties. Specifically, we examined if 
lysosomotropic anticancer agents were relatively less toxic to mice with normal 
lysosomal pH, compared to mice with elevated lysosomal pH, due to changes in 
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intracellular distribution. If this is the case then raising the lysosomal pH of mice should 
cause a redistribution of a lysosomotropic drug from lysosomes, which would allow the 
drug to interact with the intended target molecules and exert its toxic effects to a greater 
degree.  Conversely, since the intracellular distribution of non-lysosomotropic 
compounds is not influenced by the lysosome-to-cytosol pH gradient, the toxicity of such 
drugs should not be affected by changes in lysosomal pH.  
To elevate lysosomal pH in mice, we used chloroquine, which has been shown to 
raise lysosomal pH in cultured cells [2] and developed an assay to determine the impact 
of chloroquine treatments on lysosomal pH in mice. Toxicity of Hsp90 inhibitors was 
evaluated by assessing morbidity, and by utilizing biochemical assays to diagnose hepatic 
and renal toxicity. Consistent with previous in vitro results, toxicity of the lysosomotropic 
inhibitor 17-DMAG was significantly enhanced in mice with elevated lysosomal pH 
relative to mice with normal lysosomal pH. Conversely, elevation of lysosomal pH had 
no significant impact on toxicity of the non-lysosomotropic inhibitor, geldanamycin 
(GDA). The fact that CQ treatment had no impact on GDA toxicity serves as an 
important control, since it shows that CQ treatment does not enhance the toxicity of 
Hsp90 inhibitors in general, but only that of inhibitors with lysosomotropic properties. 
Therefore, our results support the notion that the low lysosomal pH of normal cells plays 
an important role in protecting normal tissues from the toxic effects of anticancer agents 
with lysosomotropic properties. These results have implications for the design/selection 
of anticancer drugs with improved safety and differential selectivity.  
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4.2. Materials and Methods 
4.2.1. Animals  
The present study was performed with approval from the University of Kansas 
Institutional Animal Care and Use Committee (IACUC). Male Balb/C mice (10-12 weeks 
old) were obtained from the Charles River Laboratories (Wilmington, MA). Animals 
were housed under standard conditions in a 12-h light/dark cycle and with free access to 
commercial food pellets and water.  
 
4.2.2. Chemicals 
 Geldanamycin (GDA) was obtained from LC Laboratories (Woburn, MA), and 
17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17-DMAG) was synthesized 
and characterized by Dr. Laird Forrest according to a previously published method [3]. 
All other reagents were obtained from Sigma (St. Louis, MO), unless otherwise stated. 
 
4.2.3. Drug treatments and morbidity evaluations in mice 
  Dosing protocols for the Hsp90 inhibitors, GDA and 17-DMAG, were 
experimentally arrived at by determining a regimen that resulted in symptoms of acute 
toxicity (morbidity) in approximately 20% of animals in a treatment group (n = 10). 
Accordingly, 17-DMAG was administered i.p. at a dose of 75 mg/kg on days 1-2, and 30 
mg/kg on day 3.  GDA was administered i.p. at a dose of 3.5 mg/kg on days 1-4 and 7 
mg/kg on days 5-9. To elevate lysosomal pH in mice, indicated groups of mice were 
pretreated with 50 mg/kg/day chloroquine [4] by i.p. administration for 5 days prior to, 
and concurrent with, dosing of the Hsp90 inhibitors at the aforementioned doses.  During 
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concurrent dosing of CQ and Hsp90 inhibitors, CQ was administered 2-3 hours prior to 
Hsp90 inhibitor treatment. CQ and 17-DMAG were reconstituted in normal saline (200 
µL) and GDA was dissolved in neat DMSO (30 µL/dose) for i.p. administrations.  The 
day after completion of dosing, the presence of morbid symptoms was determined by an 
experienced blinded observer.  Animals were considered morbid if they were severely 
immobile, hunched in posture, experiencing severe diarrhea, hypothermic, not eating 
and/or if they were unresponsive to noise. At the conclusion of treatments (days 4 and 10 
for 17-DMAG and GDA, respectively), or after signs of morbidity were detected, mice 
were euthanized via cardiac puncture and exsanguinations. 
 
4.2.4. Elevation and measurement of lysosomal pH in mice 
To elevate lysosomal pH in mice, i.p. injections of 50 mg/kg/day CQ diphosphate 
were given for five days (untreated group received i.p injections of saline). To evaluate 
the effect of CQ treatment on lysosomal pH, mice were dosed via tail vein injection with 
100 μL of a 5 mg/ml solution of the pH responsive dye, Oregon Green 488 conjugated to 
70,000 MW dextran (Invitrogen, CA). Dextran polymers of this molecular size are 
known to extensively localize in the liver shortly after administration [5]. Whole livers 
were imaged using the Maestro In Vivo Imaging System (Woburn, MA) to confirm 
fluorescence probe localization in the liver. To determine lysosomal pH, hepatocytes 
were isolated from mice dosed with Oregon Green dextran 6h after dosing (to allow 
Oregon Green dextran to localize in lysosomes), using a previously published technique 
[6], with modifications. Following sacrifice via cardiac puncture and exsanguination, 
mouse organs were perfused through an incision in the left ventricle at a flow rate of 7 
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mL/min using the following buffers and times of perfusion: i) perfusion buffer A, 
containing 142 mM NaCl, 6.7 mM KCl, 25 mM NaHCO3 (adjusted to pH 7.4 with 1N 
HCl) for 5 min; ii) perfusion buffer A to which 0.5mM EGTA was added, for 5 min; iii) 
perfusion buffer A for 3 min and; iv) perfusion buffer A containing 0.05% 
collagenase/dispase (Roche Diagnostics, Indianapolis, IN) and 5mM CaCl2 for 5 min. 
During the procedure, perfusate was drained via an incision in the right atrium of the 
heart. Livers were excised and collected into the solution containing perfusion buffer A 
with 0.05% collagenase and 5 mM CaCl2. Livers were subsequently minced under sterile 
conditions using a scalpel and incubated at 37°C for 10 min with occasional agitation. 
The cell suspension was filtered through a 100 µM cell strainer (Fisher, Woburn, MA). 
The filtrate was then centrifuged at 50g for 5min and the pellet washed twice in buffer B 
containing 142 mM NaCl, 6.7mM KCl, 1.2 mM CaCl2, 10 mM Hepes, pH 7.4. 
Lysosomal pH was then measured using a previously published technique [7,8,9]. 
Briefly, freshly isolated hepatocytes were re-suspended in pH 7.4 buffer containing 
150mM NaCl, 20mM Mes, 5mM KCl, and 1mM MgSO4. Cells were placed onto a 
microscope slide, sealed with a cover slip and the ratio of Oregon Green emission at 495 
and 450 nm excitation measured through a 525/10 nm band pass filter using a microscope 
adapted Ratiomaster spectrofluorimeter (PTI, Trenton, NJ), equipped with a 
photomultiplier tube detector. To create a calibration curve for pH determination  
isolated hepatocytes  were separately resuspended in pH 4, 5, 5.5, 6 or 7 buffers 
containing the ionophores nigericin (10 μM) and monensin (20 μM) as previously 
described [7,10]. 
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4.2.5. Fluorescence microscopy   
To confirm whether the Oregon Green-labeled dextran administered to mice was 
localized in lysosomes 6 hours after i.v. injection in mice, freshly isolated hepatocytes 
were incubated with 50-100 nM LysoTracker Red (Invitrogen, CA), for 30 min at 37 °C, 
washed twice with PBS and viewed with an Olympus spinning disk confocal microscope 
using the appropriate filter sets to visualize Oregon Green 488 and LysoTracker (LTR) 
Red. To visualize colocalization, images obtained by the respective filters were overlaid 
using Metamorph Software (Version 7.0). To evaluate the influence of CQ-induced 
elevation of lysosomal pH on intracellular distribution of LTR, normal skin fibroblasts 
(CRL-2076, ATCC, Manassas, VA) were plated on coverslips sterilized with 90% 
ethanol followed by irradiation with UV light for 1h, and allowed to adhere overnight. 
Labeling of cells with LTR was then carried out as described above. Cells pre-treated 
with CQ were labeled with 100µM CQ for 30 min, prior to co-incubation for a further 
30min with LTR. HL60 cells (suspension) were labeled by replacing growth media with 
media containing 100nM LTR after centrifugation at 1200g using an Eppendorf 
microcentrifuge. After rinsing X3 with PBS, adherent cells on coverslips were inverted 
onto microscope slides, and sealed. Suspension cells were pipetted onto slides, coverslips 
placed over them, sealed and imaged. Images were acquired using a Hamamatsu Orca-ER 
camera mounted on a Nikon 80i upright epifluorescence microscope, through a Cy3 
filter.  
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4.2.6. Biochemical assays of serum arginase activity and serum creatinine 
  At the time of euthanasia, blood was collected into heparinized microcentrifuge 
tubes and centrifuged in a Mini Spin Plus Eppendorf Centrifuge (Hamburg, Germany) for 
10 min at 4000 rpm. Plasma was immediately collected and stored at -80°C until assays 
to evaluate hepatic and renal toxicity were performed. To comparatively assess hepatic 
toxicity, a commercially available colorimetric arginase activity kit (BioAssay systems, 
Hayward, CA) was utilized according to the manufacturer‘s instructions. Samples were 
desalted prior to analysis using desalting spin columns (Pierce, Rockford, IL). To assess 
renal toxicity, a commercial creatinine assay kit (BioVision, Mountain View, CA) was 
utilized according to manufacturer‘s instructions. Prior to analysis, samples were depleted 
of protein using a 10,000 MW cut-off filter (Millipore, MA). 
 
4.2.7. Analysis of tissue/plasma drug concentrations 
 4.2.7.1. Drug treatments 
To determine drug concentrations in tissue and plasma, mice were dosed twice 
with 50mg/kg/day 17-DMAG and 15 mg/kg/day GDA. Mice pre-treated with 
chloroquine to elevate lysosomal pH received 50 mg/kg chloroquine diphosphate for 5 
days prior to, and concurrent with dosing with Hsp90 inhibitors. Mice were sacrificed via 
cardiac puncture and exsanguination 15 min and 3h, respectively, after administration of 
the second dose of Hsp90 inhibitors. Plasma samples were collected as described 
previously and stored at -80°C until analysis of drug concentration was performed. Prior 
to organ collection, organs were perfused, as described previously, with PBS at a flow 
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rate of 8 mL/min for 5min. Liver, kidneys, heart, lungs and spleen were harvested and 
stored at -80°C. 
 
4.2.7.2. Sample preparation and HPLC analysis 
N-phenyl-1-naphthylamine was used as an internal standard (IS). Prior to drug 
extraction, tissue samples were weighed and homogenized in 0.5 -1mL PBS containing 
IS using a Sonic Dismembrator Model 500 (Fisher Scientific, Pittsburg, PA) tissue 
homogenizer. Samples were mixed with acetonitrile or ethyl acetate (1:1 v/v) for 
extraction of 17-DMAG and GDA, respectively. Samples were vortexed for 15s each, 
then centrifuged at 16100g for 10min. The organic phases were removed and evaporated 
to dryness under vacuum centrifugation. Samples were reconstituted in initial mobile 
phase and analyzed using an Agilent Series 1200 HPLC system equipped with a binary 
pump, autosampler and variable wavelength detector. For analysis of 17-DMAG, mobile 
phase A consisted of 50mM acetic acid containing 10mM triethylamine [11] and B 
consisted of methanol containing 10mM TEA. UV absorbance was monitored at 332 nm. 
A step gradient elution method was employed as follows: 70-90 % B in 10min, 90-70%B 
in 1min and maintained at 70% B for 3 min. For analysis of GDA, mobile phase A 
consisted of 2% methanol in 0.1% formic acid in H2O and B consisted of 95% methanol 
in 0.1% formic acid in H2O. An isocratic elution method using 85% B was employed. UV 
absorbance was monitored at 308 nm. Standard curves were constructed by plotting the 
peak area ratio of 17-DMAG and GDA to that of the internal standard against 
concentration, and were linear in the range studied. Linear regression was used to 
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determine the equation of line of best fit. The result of the regression analysis was used to 
determine analyte concentrations in tissue and plasma samples.  
 
4.2.8. Histopathology.  
Tissue samples from euthanized mice were preserved in 10% neutral buffered 
formalin at the time of sacrifice.  Samples were processed for routine automated paraffin 
infiltration and embedding.  Paraffin blocks were sectioned at 5µm and stained with 
hematoxylin and eosin.  Sections were processed and evaluated by a board certified 
veterinary pathologist who interpreted the specimens without information regarding 
treatment protocol (i.e. a blinded study).   Histological changes were scored for severity 
of injury on a scale of 1 to 5 (5 being most severe), after a preliminary review of all slides 
to determine the range of lesions.   Microscopic descriptions and diagnoses were then 
determined. 
 
4.2.9. Statistical Analysis.  
Data presentation and statistical analysis was carried out using Sigma Plot 10.0 
(SPSS, Chicago, IL). Data is represented as means with standard deviation where 
applicable. Statistical analyses of significance (p values) were derived from one-tailed t-
tests. 
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4.3. Results 
4.3.1. Lysosomal pH elevation in mice 
  According to our proposed drug selectivity platform, the low lysosomal pH of 
normal cells plays an important role in protecting tissues from the harmful effects of 
anticancer agents with lysosomotropic properties due to their extensive sequestration in 
this compartment.  To test this theory in vivo requires a procedure to significantly raise 
the lysosomal pH in the cells of mice to levels that have been previously observed for 
cancer cells with defective acidification in vitro (~ pH 6), such as was measured for the 
MCF-7 cell line [12]. Elevating lysosomal pH in cultured cells is routinely done using a 
number of different approaches but, to our knowledge, such approaches have not been 
previously established in vivo.  Inhibitors of the vacuolar-HP
+
P-ATPase, such as 
concanamycin A, are effective agents in raising lysosomal pH [13]; however, their use in 
animals has not been previously established.  Alternatively, the anti-malarial drug 
chloroquine [4] is known to be very well tolerated in both humans and animals and is 
known to raise lysosomal pH in cultured cells. To examine if this compound altered 
lysosomal pH in vivo, we utilized the pH sensitive dye (Oregon Green) attached to high 
molecular weight dextran polymers to determine lysosomal pH.  Mehvar and coworkers 
have previously shown that 70,000 MW dextran polymers localize predominantly in the 
liver shortly after a tail vein injection in mice and their concentration in this organ 
remains virtually unchanged for up to 48 hours afterwards [5].  We therefore injected 
70,000 MW Oregon Green-labeled dextran into the tail vein of mice and visualized 
dextran localization in livers by extracting and imaging the organ. In both treatment 
groups, dextran was significantly associated with the liver (Figure 4.1). In the 
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immunolocalization studies described in Chapter 2 to evaluate the time-dependent 
localization of high-molecular weight dextran in lysosomes, we found that 6h was 
sufficient amount of time for endocytosed dextran molecules to traverse through the early 
and late endocytic compartments and predominantly localize within lysosomes.  We 
therefore waited 6 hours to allow the dextran that accumulated in the liver to reach 
terminal lysosomes.  To confirm whether the Oregon Green labeled dextran was localized 
in lysosomes prior to determination of lysosomal pH; isolated hepatocytes were labeled 
with the lysosomal vital stain, LysoTracker Red. Oregon Green dextran was found to 
significantly colocalize with LysoTracker Red, which suggests that the dextran was 
predominantly localized within lysosomes (Figure 4.2). Evaluating ratios of the 
fluorescence intensities at different wavelengths allowed us to estimate liver cell 
lysosomal pH in untreated mice to be 4.2 ± 0.2 (n=3), which is in close agreement with 
previous reports on normal lysosomal pH [10,14]. Dosing mice with CQ i.p. (50 
mg/kg/day for 5 days) resulted in a significant elevation in lysosomal pH to a value of 5.6 
± 0.3 (n=3).  Although these treatments with CQ are higher than typical therapeutic doses 
administered to mice, which is typically 10mg/kg i.p. for 3-4 days [15], there were no 
visible side effects or toxicities in mice (data not shown). CQ was subsequently used to 
examine the influence of elevated lysosomal pH on anticancer drug toxicity in mice in the 
remainder of the studies.  
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Figure 4.1. Oregon Green dextran (70 kD) localizes extensively in livers of CQ-
treated and untreated mice.  Mice were dosed with 50 mg/kg/day chloroquine i.p. (or 
with normal saline vehicle control) for 5 days prior to a tail vein injection of 0.5 mg 
Oregon Green-labeled dextran. To confirm dextran localization, livers were extracted and 
imaged using the Maestro In Vivo Imaging system. Lysosomal pH of liver cells was 
found to be significantly elevated in mice treated with CQ. Lysosomal pH values were 
obtained by calibration intracellular pH to known values using the ionophores nigericin 
(10µM) and monensin (20µM). The microscopically determined lysosomal pH values 
obtained from mice livers, with or without CQ treatment, are shown (pH values are mean 
± SD, n=3) 
 
 
4.3.2. Influence of lysosomal pH on drug-induced morbidity in mice  
 The selectivity platform examined in this work relies on the assumption that 
weakly basic lysosomotropic anticancer agents will distribute extensively into lysosomes 
of normal cells, which will diminish their ability to interact with target molecules that are 
localized outside of this compartment.  For Hsp90 inhibitors, the target molecules 
(Hsp90) are thought to be primarily localized in the cell cytosol [16]. 17-DMAG is 
weakly basic  with a pKa value of 7.6 and has been previously shown to localize in 
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lysosomes of cells with normal pH regulation [17]. Accordingly, in mice pretreated with 
CQ to elevate lysosomal pH, the lysosomotropic inhibitor should undergo some degree of 
redistribution from lysosomes to the cytosol, which would enhance interactions with 
Hsp90 and increase the effectiveness (toxicity) of the drug. 
 
 
 
 
 
 
 
 
 
 
Figure 4.2. Intravenously delivered Oregon Green 488–conjugated 70,000 MW 
dextran localizes predominantly in lysosomes after 6h. Mice were dosed with 0.5 mg 
Oregon Green dextran via the tail vein, and hepatocytes isolated 6h later. To determine 
the intracellular localization of dextran, hepatocytes were labeled with the lysosome vital 
stain, Lysotracker Red. Dextran (green) colocalizes significantly with the lysosome stain 
(red), which indicates that the dextran conjugated pH probe was localized in lysosomes 6 
hours after i.v. injection. Hepatocytes were isolated using collagenase digestion (see 
Materials and Methods), labeled with 50nM Lysotracker Red for 30min at 37°C and 
viewed using confocal microscopy. 
 
 
 
 To test this hypothesis, we established a dose of 17-DMAG that caused morbidity 
in approximately 20% of normal mice.  Subsequently, the change in the extent of 
morbidity in mice following pre-treatment with CQ was evaluated (Figure 4.3). 
Morbidity assessments were carried out as outlined in Materials and Methods by an 
experienced observer who was blinded to the experimental treatments. The number of 
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morbid animals in each group were counted and represented as a percentage of the total 
number of mice per treatment group. Consistent with our hypothesis, mice with elevated 
lysosomal pH experienced significantly greater morbidity compared to those with normal 
lysosomal pH that received the same dose drug. 
Despite the fact that neither the drug vehicles (normal saline or DMSO) nor CQ 
treatment alone resulted in any morbidity to mice at the doses employed (0/10 morbid), it 
is possible that the CQ treatment could cause some additive toxicity unrelated to the 
changes in lysosomal pH when co-administered with 17-DMAG.  To address this we 
additionally examined the impact of CQ pretreatment on morbidity in mice dosed with 
the neutral, non-lysosomotropic inhibitor GDA. CQ pretreatment had no impact on 
morbidity in mice dosed with the neutral, non-lysosomotropic inhibitor GDA.  As with 
17-DMAG, we arrived at a dosing regimen of GDA that caused approximately 20% of 
the group to show signs of morbidity and subsequently examined the influence of CQ 
pretreatment on GDA-induced toxicity. CQ-pretreated mice experienced no significant 
increase in morbidity when dosed with GDA (Figure 4.3).   
 
4.3.3. Influence of lysosomal pH on drug-induced changes in liver and kidney 
function 
To quantitatively assess the trends observed with the previously described 
morbidity evaluations, biochemical assays of liver and kidney function were performed 
on plasma samples from mice in all treatment groups. The toxicity of Hsp90 inhibitors 
has previously been shown to be primarily associated with liver and kidneys [18]. 
Therefore, the effect of treatment on the function or integrity of these organs was 
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comparatively assessed for each drug treatment with or without CQ pretreatment. Serum 
arginase levels were measured as a specific diagnostic of liver integrity. Arginase I has 
been evaluated as a Arginase I has been evaluated as a highly-specific hepatotoxicity 
marker, and its activity is found to be elevated in the serum of animals as a result of liver 
damage or injury [19]. Consistent with previous morbidity results, mice treated with 17-
DMAG alone had relatively low serum arginase activities, while CQ pre-treatment prior 
to 17-DMAG treatment resulted in significantly elevated arginase activity levels 
consistent with increased liver damage (Figure 4.4).  Conversely, the CQ pre-treatments 
resulted in no significant change in serum arginase levels (p>0.01) in mice treated with 
the non-lysosomotropic inhibitor GDA (Figure 4.4). Creatinine levels in serum are 
routinely used as an indicator of renal function.  An increase in serum creatinine indicates 
defective renal function that may be caused by drug toxicity. We therefore measured the 
levels of creatinine in plasma of all drug treatment and control groups. We observed no 
statistically significant differences in serum creatinine levels between control and CQ 
pre-treated mice receiving 17-DMAG, which could be attributed to high levels of animal-
to-animal variability in creatinine levels (Figure 4.5). Serum creatinine levels in GDA 
treated mice were significantly higher than control (p<0.01), but as expected, there was 
no difference in serum creatinine levels with or without CQ pre-treatment. Compared to 
control mice, there was no significant change in serum arginase activity and creatinine 
levels (p>0.01) in mice dosed with CQ alone, GDA vehicle (DMSO) alone or CQ and 
DMSO together (Figures 4.4 and 4.5).  
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Figure 4.3. Elevations in lysosomal pH enhance drug-induced morbidity in mice 
treated with the lysosomotropic inhibitor 17-DMAG, but not when treated with the 
neutral inhibitor GDA. The percentage of mice determined to show symptoms of 
morbidity for each of the indicated treatment groups are shown (n=10 per indicated group).  
Mice treated with CQ and 17-DMAG experienced greater incidences of morbidity 
compared to mice receiving equivalent doses of 17-DMAG alone.  No significant changes 
in morbidity were observed for mice receiving GDA with CQ pretreatment.  17-DMAG 
was administered i.p. at a dose of 75 mg/kg on days 1-2, and 30 mg/kg on day 3.  GDA was 
administered i.p. at a dose of 3.5 mg/kg on days 1-4 and 7 mg/kg on days 5-9.  Where 
indicated, CQ was administered at a dose of 50 mg/kg/day i.p. for 5 days prior to and 
concurrent with indicated Hsp90 inhibitor treatments.  Morbidity was evaluated by a 
blinded observer during Hsp90 inhibitor dosing, as described in Materials and Methods. 
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Figure 4.4. Elevations in lysosomal pH induced by CQ treatment enhance drug-
induced liver toxicity in mice treated with the lysosomotropic Hsp90 inhibitor 17-
DMAG, but not when treated with the neutral inhibitor GDA.  Arginase I activity 
was measured in the plasma of control mice (no treatment), CQ-treated mice, mice 
receiving GDA vehicle (DMSO), mice receiving both DMSO and CQ, and mice treated 
with indicated Hsp90 inhibitors with or without CQ pre-treatment.  Dosing regimens are 
described in the legend of Fig. 2.  Bars, means ± SD for indicated Hsp90 inhibitor 
treatments with or without CQ treatment (n=6) and for control and CQ-treated groups of 
mice (n=4). *, p < 0.01; **, p > 0.05 
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Figure 4.5. CQ-induced elevations in lysosomal pH have no significant impact on 
renal toxicity induced by indicated Hsp90 inhibitor treatments. Creatinine levels was 
measured in serum of control (no treatment), CQ-treated mice, mice receiving GDA 
vehicle (DMSO), mice receiving DMSO and CQ, and mice treated with indicated Hsp90 
inhibitors with or without CQ pre-treatment. Dosing regimens are described in the legend 
of Fig. 2. Bars, means ± SD for indicated Hsp90 inhibitor treatments (n=6) and for 
control and CQ-alone treated groups (n=4). 
 
 
4.3.4. Tissue/plasma drug concentrations 
The difference in toxicity observed for 17-DMAG upon CQ pretreatment could 
theoretically result from CQ-induced alterations in tissue distribution or 
pharmacokinetics of Hsp90 inhibitors. Accordingly, to evaluate this possibility, the tissue 
and plasma drug concentrations of 17-DMAG and GDA with and without CQ-pre-
treatment were measured using UV-HPLC. Representative chromatograms of 17-DMAG 
and GDA with internal standard (n-phenyl-1-naphthylamine) in mobile phase are shown 
(Figure 4.6). Calibration curves were constructed by plotting the peak area ratio of the 
respective analytes to the internal standard against concentration of analyte. Using these 
calibration curves, the concentration of drug in plasma, liver, kidneys, spleen, lungs and 
heart were evaluated at 15 min (predicted peak time) and 3 h after administration of 
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Hsp90 inhibitors.  These time points were selected based on previously published 
pharmacokinetic profiles of 17-DMAG [18] and GDA [20].  We found no significant 
impact of CQ treatment on tissue/plasma drug concentration ratios of 17-DMAG in all 
organs evaluated (Figure 4.7). Likewise, tissue/plasma concentrations obtained for GDA 
were not found to be significantly influenced by CQ pretreatment (Figure 4.8). 
Collectively, these results suggest that the enhanced 17-DMAG-induced toxicity found to 
occur after CQ treatment likely resulted from changes in intracellular distribution of 17-
DMAG and cannot be attributed to an increased overall exposure of the organs to the 
drug.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
17-DMAG
I.S.
GDA
I.S.
Figure 4.6. Representative gradient elution chromatograms of 17-DMAG and GDA 
with I.S. (N-phenyl-1-naphthylamine). All three compounds were reconstituted at 
100µg/ml in mobile phase and eluted as described in Materials and Methods. 
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Figure 4.7. CQ-pre-treatment has no significant impact on 17-DMAG tissue uptake 
and distribution in mice. Tissue/plasma drug concentration ratios in indicated tissues 
are shown for mice at A, 15 min and B, 3 h hours post i.p. administration of 17-DMAG. 
Mice were treated with 50 mg/kg/day 17-DMAG for two days, and sacrificed 15 min and 
3 h respectively after the last dose of 17-DMAG. Where indicated, CQ was administered 
i.p. as described in the legend of Fig. 2. Bars, means ± SD for Hsp90 inhibitor 
concentration with or without CQ treatment.  *, p > 0.01 
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Figure 4.8. CQ-pre-treatment has no significant impact on uptake and tissue 
distribution of GDA. Tissue/plasma drug concentration ratios in indicated tissues are 
shown 15 min post i.p. administration of GDA. Mice were treated with 20 mg/kg/day 17-
DMAG for two days. Where indicated, CQ was administered at a dose of 50 mg/kg/day 
i.p. for 5 days prior to and concurrent with GDA. Bars, means ± SD in indicated tissues. 
*, p > 0.05; ‡, concentrations below the limit of quantitation. 
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Figure 4.9. Tissue accumulation of 17-DMAG and GDA. 17-DMAG and GDA     
have significantly different tissue distribution profiles. Shown are the molar 
concentrations per gram tissue in indicated organs for A, 17-DMAG and B, GDA 
15 min after administration of Hsp90inhibitors. Mice were dosed with 50 
mg/kg/day 17-DMAG and 15 mg/kg/day GDA for two days. Bars, means ± SD in 
indicated tissues. *, p < 0.01; **, p >0.05; ‡, concentrations below LOQ 
 
 
4.3.5. Tissue histopathology evaluations 
To further characterize results obtained from analyzing morbidity, organs were 
examined for the presence of drug-induced lesions or injury.  Lung, liver, spleen and 
kidney histological examinations were performed on hematoxylin and eosin-stained 
sections from each treatment group using light microscopy.  All sections were reviewed 
and scored for severity of morphological changes (scale 1-5, 5 being the worst), and an 
overall diagnosis was determined by a veterinary pathologist. Of all the organs evaluated, 
only the liver showed consistent and significant histological changes upon different 
treatment protocols examined in this study.  Shown are representative liver specimens 
from each treatment group (Figure 4.10).  A summary of liver diagnosis and hepatic 
necrosis severity scores are listed in Table 4.1.  Histological sections of livers from 
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saline-treated (control) mice were populated with normal hepatocytes having intact nuclei 
and cytoplasm (Figure 4.10 A). Sections obtained from mice treated with CQ alone 
(Figure 4.10.B) were not visibly different from the untreated control group (Figure 4.10 
A). Histological sections obtained from mice with unaltered (normal) lysosomal pH that 
were dosed with 17-DMAG (Figure 4.10.C) also appeared similar to control sections 
(Figure 4.10.A).  In contrast, liver sections from mice with elevated lysosomal pH (CQ-
treated) and subsequently dosed with 17-DMAG were characterized as having many dead 
cells devoid of nuclei, or cells with fragmented nuclei as well as pale staining cytoplasm, 
all features characteristic of hepatic necrosis (Figure 4.10.D). Moderate to severe hepatic 
necrosis was diagnosed in all sections examined in this treatment group (Table 1).  
Sections of mice receiving DMSO (Figure 4.10.E) and both DMSO and CQ (Figure 
4.10.F) were similar to sections of mice receiving saline only (Figure 4.10.A). Both 
groups of GDA-treated mice, with normal (Figure 4.10.G) and elevated lysosomal pH 
(Figure 4.10.H), had signs of hepatic necrosis. Histological sections in these groups were 
significantly different from those of control mice and were characterized as having mild 
to severe hepatic necrosis. The histological analysis of is summarized in Table 1.  
 
4.3.6. Influence of lysosomal pH on intracellular distribution of the weakly basic 
amine Lysotracker Red 
According to our hypothesis, increased toxicity of 17-DMAG upon treatment with 
CQ was due to a redistribution of 17-DMAG from the lysosome to the cytosol as a 
consequence of the elevated lysosomal pH. Since this proposed re-distribution of drug 
cannot be readily evaluated, since 17-DMAG is not fluorescent, we evaluated the 
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intracellular distribution of Lysotracker Red (LTR) with and without CQ pre-treatment of 
normal fibroblasts. LTR has a pKa value nearly identical to 17-DMAG (7.5 versus 7.6, 
respectively), and should therefore have similar pH-dependent changes in intracellular 
distribution. In normal human fibroblasts with low lysosomal pH, LTR is almost 
exclusively localized in acidic lysosomes, with very little accumulation in the cytosol 
(see Figure 4.11). In CQ-pre-treated cells, LTR is still localized to lysosomes; however, 
the degree of sequestration is reduced and LTR has noticeably redistributed to the cytosol 
to a greater extent than in control cells.  This is particularly evident under high 
magnification (see Figure 4.11).  This observation is consistent with the implication that 
in CQ-pretreated mice, 17-DMAG distributes to a greater extent in the cytosol, which 
promotes interactions with cytosolic Hsp90 and therefore greater drug-induced toxicity is 
observed.   
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Figure 4.10. Elevations in lysosomal pH due to CQ treatment enhance drug-induced 
liver damage in mice treated with the lysosomotropic inhibitor 17-DMAG, but not 
when treated with the neutral inhibitor GDA. A-H, photomicrographs of hematoxylin and 
eosin stained liver sections from control mice and from those treated with Hsp90 inhibitors 
with or without CQ pre-treatment.  The panels illustrate representative photomicrographs 
from: A, control mice; B, mice treated with CQ alone; C, mice treated with 17-DMAG 
alone; D, mice treated with 17-DMAG following CQ pre-treatment; E, mice treated with 
DMSO; F, mice treated with DMSO and CQ, G, mice treated with GDA alone; and H, mice 
treated with GDA following CQ pre-treatment. Panels A, B, C, E and F illustrate 
hepatocytes with intact nuclei and cytoplasm with no diagnosis of necrosis reported (Table 
1). Panels D, H, and G all show hepatocytes with condensed chromatin or lacking nuclei, 
and pale staining cytoplasm characteristic of advanced necrosis (Table 1).  
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     Table 4.1.  Summary of liver section diagnosis following indicated treatments 
 
 
 
Treatment Liver diagnosis Severity 
scores 
 
Saline 
 
Normal appearance 
 
0, 0 
 
DMSO Normal appearance 0, 0 
 
CQ Normal appearance 0, 0 
 
DMSO + CQ Normal appearance 0, 0 
 
DMAG Normal appearance 0, 0 
 
DMAG + CQ Moderate to severe hepatic necrosis 4, 3 
 
GDA Moderate to severe hepatic necrosis 4, 3 
 
GDA + CQ Mild to severe hepatic necrosis 4, 2 
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Figure 4.11. The lysosomotropic fluorophore Lysotracker Red has enhanced 
cytosolic localization in cells with elevated lysosomal pH (CQ-treated) 
relative to untreated cells.  Normal fibroblasts have a low lysosomal pH (4.2) 
and localize LTR almost exclusively in punctate compartments, which are 
presumed to be lysosomes (or other very low pH compartments).  Normal 
fibroblasts pretreated with CQ have elevated lysosomal pH and enhanced 
cytosolic fluorescence. Cells were incubated identically with Lysotracker Red 
(100nm for 30 minutes).  
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4.4. Discussion 
A great deal of anticancer drug research is directed towards the development of 
agents that have increasingly potent cytotoxic or anti-proliferative effects on a wide range 
of cancer cells.  However, very few studies have focused on systematically evaluating the 
factors that can potentially diminish the ―effectiveness‖ of such anticancer agents in 
normal cells, which would result in the identification of safer, more selective 
chemotherapeutics. Since the overall efficacy of any chemotherapeutic agent is 
determined by the difference in the degree of cytotoxicity between normal and 
transformed cells, we argue that research in the latter should be viewed as equally 
important.  
We have previously shown that the sequestration of weakly basic drugs in 
lysosomes via ion-trapping can profoundly affect drug activity in cells. In this Chapter, 
we tested the hypothesis that sequestration of anticancer drugs in lysosomes of normal 
cells plays an important role in limiting their toxic effects in vivo using mice.  Our 
previous evaluations using cultured cells have shown that anticancer agents with 
lysosomotropic properties can distribute differently in normal cells compared to cells 
with impaired lysosomal acidification, a trait common to several types of cancer cells 
[12,21]. Specifically, our results suggested that anticancer agents with lysosomotropic 
properties are extensively compartmentalized in lysosomes of normal cells, thereby 
diminishing their availability to interact with extra-lysosomal target sites. Therefore, by 
virtue of their compartmentalization in lysosomes, anticancer agents with lysosomotropic 
properties should have greater safety in normal tissues, relative to cancer cells with 
defective acidification. 
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To test this mechanism in vivo required us to modulate lysosomal pH in mice, and 
compare the toxicity of the lysosomotropic Hsp90 inhibitor 17-DMAG. Elevation of 
lysosomal pH in the livers of mice was accomplished using multi-day administrations of 
CQ as described in Materials and Methods (Figure 4.1). To our knowledge, this work 
represents the first time that quantitative elevations of lysosomal pH were evaluated in 
animals.  Raghunand and co-workers [22] have shown that the addition of NaHCOR3R to 
the drinking water of mice for several days increased the extracellular and cytosolic pH 
of MCF-7 human breast cancer xenografts in mice; however, the pH of lysosomes was 
not measured. Petrangolini and colleagues have previously evaluated an inhibitor of the 
vacuolar-HP
+
P-ATPase named NiK-12192 in mice [23].  The authors did show, for cells 
grown in culture,  that this inhibitor altered the fraction of acridine orange that yielded 
red versus green intracellular fluorescence, which is used to indicate the degree of acidity 
in cells; however, no such confirmation of pH changes were reported when the compound 
was administered orally in mice.  Interestingly, and relevant to this work, the authors 
found that when NiK-12192 was administered with the weakly basic anticancer agent 
topotecan, the combination caused enhanced generalized toxicity in mice as was 
evidenced by increased weight loss and, in one case, death. Importantly, the weight loss 
observed when these compounds were co-administered was significantly greater than the 
sum of the values obtained when treatments were administered separately.  This 
synergistic effect is analogous to the results observed when 17-DMAG and CQ were co-
administered to mice in Figure 4.3.   
Consistent with our hypothesis, we have demonstrated that mice with elevated 
lysosomal pH experienced a higher incidence of drug-induced morbidity compared to 
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mice with normal lysosomal pH when an anticancer agent with lysosomotropic properties 
was administered. Moreover, serum arginase levels (Figure 4.4.) and histological 
evaluations of livers (Figure 4.10) both indicate an increase in liver damage when 
lysosomotropic inhibitors are administered in mice with elevated lysosomal pH.  Such 
changes were not observed with the neutral Hsp90 inhibitor GDA.   
It is important to point out an apparent discrepancy associated with our findings 
that occurs when one attempts to compare GDA and 17-DMAG-induced morbidity 
(Figure 4.3) and liver toxicity (Figure 4.4). Specifically, morbidity in mice receiving 
GDA (with or without CQ pre-treatment) was found to be relatively low (~20%), yet the 
liver toxicity assessments associated with these mice were similar to that of mice treated 
with 17-DMAG and CQ that were approximately 100% morbid.  This observation 
suggests that these two drugs have different organ-associated toxicity profiles that 
ultimately lead to signs of morbidity.  We hypothesize that this has to do with differences 
in the tissue distribution profiles for the two drugs.  Using data generated for Figure 4.8, 
we have plotted the overall molar accumulation of the two drugs in all organs evaluated 
per gram of tissue (see 4.9).  From these data one can see that GDA preferentially 
accumulates to a significantly greater extent in the liver relative to other organs evaluated 
(kidney, spleen, lungs, heart).  On the contrary, 17-DMAG accumulates to approximately 
the same degree in both liver and kidneys and also has reasonably high levels in the 
remaining organs evaluated.  Based on these findings it is likely that 17-DMAG-induced 
morbidity results from cumulative low-level insult to many organs, whereas GDA has the 
majority of its toxic effects associated with the liver, and this alone does not cause overt 
signs of morbidity at the doses of GDA examined here.  It is not clear what causes GDA 
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to distribute in tissues differently from 17-DMAG.  It is possible that factors such as 
differences in protein binding could contribute to this difference. 
A significant concern with the experimental design of this work stems from the 
possibility that CQ treatment enhances the toxic effects of lysosomotropic Hsp90 
inhibitors through pathways unrelated to lysosomal pH modulation.   Our results that 
showed that CQ pretreatment caused no increase in morbidity or organ toxicity of GDA 
suggests that CQ does not generally augment the pharmacological activity of all Hsp90 
inhibitors, rather it is specific to those with lysosomotropic properties.  It is also possible 
that CQ pretreatment could selectively promote enhanced tissue uptake and retention of 
17-DMAG.  This could be the case if CQ inhibited an efflux transporter that was specific 
for 17-DMAG but not GDA.  If this were the case then we would expect that CQ 
pretreatment would cause a significant elevation of the tissue/plasma concentration ratio 
of 17-DMAG.  This was not found to be the case, for all organs evaluated (see Figure 
4.7).  Consequently, considering that CQ pretreatment does not appear to have any 
significant impact on GDA toxicity, and that CQ pre-treatment did not influence tissue 
distribution and pharmacokinetics of 17-DMAG, we concluded that the enhanced toxicity 
observed for 17-DMAG in CQ-pretreated mice was due to alterations in the drug‘s 
intracellular distribution due to the change in lysosomal pH, and not due to CQ 
modulating relevant pathways influencing its in vivo activity.  
The proposed changes in intracellular distribution of 17-DMAG as a result of 
elevation of lysosomal pH cannot be readily visualized, since this compound is non-
fluorescent. However, we propose that, in principle, other fluorescent weakly basic 
amines should have similar intracellular distribution based on ion trapping principles. The 
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amine Lysotracker Red has a pKa value nearly identical to 17-DMAG (7.5 versus 7.6, 
respectively), it should have similar pH-dependent changes in intracellular distribution. 
Since the fluorescence of LTR makes it readily detectable using fluorescence 
microscopy, we evaluated the intracellular distribution of LTR in cells grown in culture 
with or without CQ treatment, analogous to what was done in mice. In normal human 
fibroblasts with low lysosomal pH, LTR is almost exclusively localized in acidic 
lysosomes, with very little accumulation in the cytosol (see Figure 4.11). We pretreated 
the same human fibroblasts with CQ in an attempt to mimic the situation with CQ-
pretreated mice.  In these cells the LTR is still localized to lysosomes; however, the 
degree of sequestration is reduced and LTR has noticeably redistributed to the cytosol to 
a greater extent than in control cells.  This is particularly evident under high 
magnification (see Figure 4.11).  This observation is consistent with the implication that 
in CQ-pretreated mice, 17-DMAG distributes to a greater extent in the cytosol, which 
promotes interactions with cytosolic Hsp90 and therefore greater drug-induced toxicity is 
observed.   
Taken together, the current results are consistent with the perception that 
anticancer agents with optimal lysosomotropic characteristics will be safer in normal 
tissues due to their extensive compartmentalization in lysosomes. However, further in 
vivo studies using tumor-bearing mice will be required to fully examine the feasibility 
and/or limitations of this approach.  For example, one significant potential obstacle to the 
usefulness of this approach stems from the fact that the microenvironment surrounding 
solid tumors is known to be acidic relative to normal tissue. As a result, the pH gradient 
existing between the extracellular microenvironment and the cell cytosol is expanded in 
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some solid tumors relative to the pH gradient in normal tissues.  According to pH 
partitioning theory, the steady state accumulation of weak electrolytes that are membrane 
permeable in their unionized state and membrane impermeable in their ionized state will 
be determined by differences in the pH gradient existing between the cell cytosol and the 
extracellular space.  Specifically, the intracellular accumulation of weakly basic drugs is 
expected to be impaired relative to acidic or neutral compounds due to the fact that it will 
take a significantly longer time for cellular uptake of the drug due to ionization in the 
acidic exterior environment.  This has been shown to occur both in vitro and in vivo 
[24,25].  It is clear that such issues would represent an important consideration when 
treating many solid tumors that have acidic extracellular pH; however, it should not be a 
concern for all cancer types since many tumors have been shown to have normal 
extracellular pH [26].  An obvious example would be hematological cancers. Moreover, 
it is possible that the favorable intracellular distribution of weakly basic drugs inside 
cancer cells with defective lysosomal acidification could offset the aforementioned 
unfavorable accumulation differences that may exist.  Further in vivo investigations will 
be required to address these questions. 
The overall goal of enhancing anticancer drug selectivity is to reduce the systemic 
toxicity that results from the indiscriminate toxicity of traditional anticancer drugs, which 
limits the anti-tumor efficacy of most currently used anticancer drugs. The results 
presented in this Chapter suggest that purposefully targeting drugs to lysosomes of 
normal tissues may reduce the systemic toxicity of lysosomotropic anticancer drugs.  
Collectively, this work and the work presented in Chapters 2 and 3, provide strong 
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support for exploring IDB selectivity as a rational approach with great promise to 
enhance anticancer drug selectivity.  
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Chapter 5: Research summary and future directions 
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5.1. Summary and conclusions 
The lack of selectivity and resultant toxicity of anticancer drugs to normal cells 
and tissues is perhaps the most prohibitive factor to the success of chemotherapeutics. For 
this reason, continued research efforts into identifying new, rational approaches to 
enhance the selectivity of existing and future anticancer drugs are warranted. Much 
research has focused on the discovery or design of anticancer agents that have optimized 
potency against a variety of cancer cell types, while much less effort is spent on the 
design of drugs that are potent yet minimally toxic to normal cells. Using this model, a 
number of compounds are identified are not therapeutically utilizable due to unacceptable 
toxicity in vivo. However, even drugs that are developed and approved for chemotherapy 
continue to have toxicity that significantly limits their dose and efficacy. 
Much effort has been made to improve the selectivity of anticancer drugs. 
Classical efforts to enhance the selectivity of anticancer drugs have focused on the so-
called ‗magic bullet‘ approach, first proposed by Paul Ehrlich [1]. These approaches 
share a common feature, which is the attempt to enhance the delivery of active drug to 
the tumor site, while reducing the accumulation of around normal cells. Such approaches 
were reviewed in Chapter 1. 
In spite of its conceptual appeal, the magic bullet, or directed targeting approach 
has not been very successful in enhancing anticancer drug selectivity [2]. Achieving truly 
site specific delivery of a drug is in reality, very challenging, since the properties that 
make traditional anticancer drugs excellent candidates for delivery to tumors and to 
intracellular targets, also allow them to escape the site of interest after site-specific 
accumulation is achieved.   
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A rarely considered option in enhancing differential selectivity of anticancer 
drugs to cancer cells is optimizing their physicochemical features to influence their 
intracellular distribution. This is a feasible approach, given the fact that drug targets are 
often localized in discrete intracellular compartments, and that localization of drugs in 
these compartments is influenced by cellular properties that may differ between normal 
and transformed cells, thus resulting in differential intracellular drug distribution between 
normal and cancer cells. 
In this thesis, we have evaluated an intracellular drug distribution based approach 
to enhance the selectivity of anticancer drugs. This approach exploits the defective 
lysosomal pH associated with some cancer cells to enhance the selectivity of weakly 
basic anticancer drugs. Normal cells have lysosomes that are very acidic relative to the 
cell cytosol, creating a steep lysosome-to-cytosol pH gradient that facilitates the 
sequestration of weakly basic drugs in lysosomes via ion-trapping [3]. However, 
defective lysosomal acidification in some cancers [4,5] reduces the lysosome-to-cytosol 
pH gradient that provides a driving force for the accumulation of weak bases in 
lysosomes via ion trapping. This increases the cytosolic concentration of the drug in 
cancer cells, which enhances drug interactions with extra-lysosomal targets. These 
differences in intracellular distribution of weakly basic drugs in normal and cancer cells 
therefore result in enhanced activity in cancer cells relative to normal cells. 
In support of this, we found that anti-cancer drugs with basic properties were 
more toxic to cells with elevated lysosomal pH compared to cells with normal lysosomal 
pH. Conversely, the toxicity of non-lysosomotropic drugs were not influenced by the 
lysosomal pH of cells [6]. A limitation of the IDB targeting approach, however, is that it 
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would only be applicable to cancer types with defective lysosomal acidification. 
Therefore, it is important to establish the scope of defective lysosomal acidification of 
cancer cells. In Chapter 2 we evaluated the prevalence of defective lysosomal 
acidification in cancer cells, as well as the effects of transformation on lysosomal pH. 
Prior to our studies, it was unclear whether defective lysosomal acidification was a 
phenomenon associated with all cancer cells, or a subset of them. We found that while all 
normal cells evaluated had a lysosomal pH around 4, cancer cells ranged in pH from 
values close to normal to highly elevated lysosomal pH. From these studies it appears 
that although not all cancer types will be candidates for IDB selectivity, a significant 
portion of cancer cells exhibit some degree of defective lysosomal acidification that is 
sufficient for selectivity enhancement to be achieved based on this approach. It is clear 
that our lysosomal pH evaluations are very limited in scope, in part because of the low-
throughput nature of lysosomal pH evaluations. The development of a high-throughput 
approach to determine lysosomal pH can greatly advance the identification of cancer cells 
with defective lysosomal acidification and application of IDB selectivity. Interestingly, a 
method for the high-throughput screening of lysosomal pH in cells has recently been 
described [7]. 
Having established that IDB selectivity has the potential to be applied to a number 
of cancer types, we then sought to determine whether IDB selectivity can be optimized 
according to physicochemical properties that govern lysosomal sequestration. In 
preliminary studies, we had shown that weakly basic drugs were more selective to cells 
with elevated lysosomal pH [6]. In the studies outlined in Chapter 3, we investigated 
whether IDB selectivity could be optimized according to the pKa of the drug. We 
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evaluated the selectivity of a series of Hsp90 inhibitors with various pKas in cancer cells 
with defective lysosomal acidification (HL60 human leukemic cells) in comparison to 
normal human fibroblasts with normal (low) lysosomal pH. Hsp90 inhibitors with pKa 
around 8, which have optimum lysosomotropic properties, had optimum IDB selectivity. 
These results are a key finding of this work, since they suggest that IDB selectivity 
arising from differences in lysosomal pH between cancer cells, can be optimized by 
rational selection and modification of the physicochemical properties of the drug. It is 
therefore possible that drugs that can be deliberately designed to have the most ideal 
properties for lysosomal properties could conceivably achieve much greater IDB 
selectivity than was achieved using our model Hsp90 inhibitor compounds. For example, 
the ratio of the permeability of the ionized form to that of the unionized form (α), is an 
additional parameter besides pKa that can be optimized to influence lysosome-to-cytosol 
distribution ratio (see equation in Chapter 3). According to de Duve‘s theoretical 
principles of lysosomal trapping [3] and confirmed by experimental evaluations in our 
lab, the α-value has a dramatic influence on the lysosome-to-cytosol concentration ratio, 
i.e. the smaller this value becomes, the greater the ratio. Our model Hsp90 compounds 
had α-values around 0.001. It is possible that compounds with a greater α value (reduced 
permeability of the ionized species) will have even greater IDB selectivity. 
The ultimate goal of an anticancer drug targeting approach is to reduce systemic 
toxicity, therefore we further evaluated whether lysosomal trapping reduced toxicity, in 
comparison to the case where the drug was localized in the cytosol, which was outlined in 
Chapter 4. Specifically, we evaluated the toxicity of the lysosomotropic drug, 17-DMAG 
in mice with normal, low lysosomal pH, compared to its toxicity in mice with elevated 
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lysosomal pH. We found that the lysosomotropic inhibitor 17-DMAG was significantly 
less toxic to mice with normal, low lysosomal pH, presumably because the drug was 
predominantly sequestered in lysosomes. However, when 17-DMAG was administered to 
mice with elevated lysosomal pH, it was highly toxic due to decreased trapping in 
lysosomes and presumably a higher cytosolic distribution, which would increase the 
drug‘s interaction with its target hence its toxicity. On the other hand, the toxicity of the 
non-lysosomotropic drug GDA, which is not a candidate for lysosomal trapping, was not 
sensitive to changes in lysosomal pH in mice. 
The results of the in vivo study suggests that using lysosomotropic analogs of a 
drug will significantly improve its therapeutic index, which is the maximum tolerated 
dose (MTD) divided by the minimum effective dose (MED). It is not expected that the 
MED of a lysosomotropic versus non-lysosomotropic drug will change due to IDB 
selectivity. However, the significant increase in MTD for a lysosomotropic drug will 
result in a significant increase in the therapeutic index of the lysosomotropic drug. Such 
an increase in MTD allows higher doses of the drug to be administered and therefore 
increases the chances of success in achieving tumor regression before limiting toxicity is 
experienced. A summary of the effect of lysosomotropic properties and lysosomal pH on 
the MTD and MED is shown in Table 5.1.  
 
 
Collectively, the work outlined in this thesis demonstrates that differences in lysosomal 
acidification between normal and cancer cells can be exploited to enhance the selectivity 
of lysosomotropic anticancer drugs. In addition, the in vivo studies demonstrate that 
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imparting lysosomotropic properties on anticancer drugs would likely lower injury to 
normal tissues, thus improving the therapeutic index. 
 
 
Lysosomotropic 
properties of 
drug 
Tumor 
lysosomal  
pH 
Maximum 
tolerated  
dose (MTD) 
Mininum 
effective  
dose (MED) 
Therapeutic 
Index 
(MTD/MED) 
none low ↑ ↓↓ ↑ 
optimal low ↑↑ ↓ ↑ 
none elevated ↑ ↓↓ ↑ 
optimal elevated ↑↑ ↓↓ ↑↑ 
 
Table 5.2. A summary of the predicted impact of lysosomotropic properties on 
MTD, MED and therapeutic index. 
 
 
Collectively, the work outlined in this thesis demonstrates that differences in 
lysosomal acidification between normal and cancer cells can be exploited to enhance the 
selectivity of lysosomotropic anticancer drugs. In addition, the in vivo studies 
demonstrate that imparting lysosomotropic properties on anticancer drugs would likely 
lower injury to normal tissues, thus improving the therapeutic index.   
In Chapter 1, we suggested that it would be helpful to develop a drug screening 
model that would identify selective drugs early on in the drug identification and 
development process. Clearly, most anticancer drugs will have selectivity due to other 
factors unrelated to intracellular drug distribution. However, in a screen that includes a 
number of normal cells with low lysosomal pH, it will be possible to identify drugs and 
cancer cell types that would benefit from IDB selectivity. Based on our results, it seems 
prudent to include a number of normal cells with low lysosomal pH in the NCI-60 screen, 
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which would aid in the identification of cancer cells types that may benefit from IDB 
selectivity.   
Many current, clinically utilized, anticancer agents possess optimal weakly basic 
properties (i.e. weakly basic with pKa around 8) that presumably impart some degree of 
IDB selectivity. It is unlikely that these properties were intentionally engineered into the 
structures of these compounds, but they nevertheless emerged superior against those 
without lysosomotropic properties. It is therefore plausible that such anticancer drugs 
have benefited from a previously unrecognized contribution from IDB selectivity, in 
addition to the intrinsic selectivity the drug may possess. Table 5.2 shows a summary of 
weakly basic drugs and their pKa that may benefit from IDB selectivity. Based on this 
observation, and the results presented in this thesis, it is highly likely that drugs with fully 
optimized lysosomotropic properties would have an even greater selectivity to cancer 
cells.  
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6.5 Mechlorethamine 
7.2 Lapatinib 
7.7 Imatinib 
7.2 Gefitinib 
5.7 Flavopiridol 
5.4 Erlotinib 
8.5 Idarubicin 
7.7 Epirubicin 
8.2 Doxorubicin 
6.8 Dasatinib 
5.1 Altretamine  
8.4 Thioguanine 
9.0 Sunitinib 
5.4 Vinorelbine 
7.7 Vindesine 
7.4 Vincristine 
7.4 Vinblastine 
6.8 Procarbazine 
8.4 Pixantrone 
8.2 Mitoxantrone 
6.5 Mitomycin 
9.5 Melphalan 
pKa pKa
 
Table 5.2. A summary of various anticancer drugs with lysosomotropic properties 
 
 
 
5.2. Future studies: Expanding the scope of IDB selectivity 
Although many cancer drugs on the market may have inadvertently benefitted 
from features that impart IDB selectivity, a number of anticancer drugs currently on the 
market lack lysosomotropic properties. Moreover, there are a number of drugs that were 
found to be active against cancer, but did not find therapeutic utility due to unacceptable 
toxicity. It would be beneficial to determine whether the selectivity and toxicity profiles 
of such drugs can be improved by modifying them to have lysosomotropic properties that 
would impart IDB selectivity. Drugs that are ideal for modifications that would impart 
IDB selectivity are non-lysosomotropic anticancer drugs (neutral or weakly acidic) that 
possess sites on their chemical structures that can withstand modification without 
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influencing the potency of the parent molecule. For many existing drugs, structure-
activity relationships have been carried out that can help in identification of the ideal sites 
for modification.  
An example of a drug that was studied for its potent anticancer activity, but was 
not further developed due to unacceptable toxicity is colchicine. The structure of 
colchicine (see Figure 5.1) indicates that this compound is not a candidate for lysosomal 
sequestration. However, there exist sites on this molecule that can be modified to impart 
selectivity, as described by Chen et al. [8]. 
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Figure 5.1 Structure of colchicine 
 
 
Similar to the approach described in Chapter 3, where weakly basic analogs of the non-
lysosomotropic Hsp90 inhibitor geldanamycin were synthesized, we propose to 
synthesize amine derivatives of compounds such as colchicine and evaluate the impact of 
such modification on selectivity and toxicity. To verify that potency of the parent drug is 
not impacted by the modifications, we will evaluate IC50 of the amine derivatives in 
comparison to the parent drug in a number of cancer cells. The enhancement in 
selectivity achieved by imparting lysosomotropic properties will be evaluated as 
described in Chapter 3, using cancer cells with defective lysosomal acidification and 
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normal cells with low lysosomal pH. However, to most accurately evaluate the 
contribution of intracellular drug distribution on selectivity, it is ideal to evaluate 
selectivity in a pair of cell lines that are otherwise identical but differ in lysosomal pH. 
Such a model was achieved using a gene silencing approach that reduced the expression 
of subunit V1E1 of the V-ATPase resulting in elevated lysosomal pH.  Using this model 
we can compare the activity (IC50) in the same cell that has normal lysosomal pH and 
compare this to the toxicity observed with cells that have elevated lysosomal pH (i.e., 
cancer like). In order to determine whether imparting IDB selectivity on the compounds 
has a positive impact on the drug‘s toxicity profile, the maximum tolerated dose (MTD) 
of the parent drug and the amine analog will be evaluated. The results of these studies 
will reveal whether drugs such as colchicine that were discarded due to unacceptable 
toxicity can be reclaimed.  
It is important to note that defective acidification of lysosomes in cancer cells is 
not the only difference between normal and cancer cells that can be exploited to enhance 
selectivity.  Mitochondria have recently received a lot of attention as potential targets for 
anticancer drugs, particularly due to the fact that they are the center for apoptotic 
signaling in the cell [2]. Selective activation of cell death pathways in cancer cells is 
therefore a potential therapeutic route for selective anticancer therapy. Interestingly, some 
cancer cells have been shown to have hyperpolarized mitochondrial membranes i.e. a 
greater membrane potential, than normal cells [9]. For example, it was shown that the 
colon carcinoma cell line CX-1 had a 60mV difference in membrane potential compared 
to normal kidney epithelial cells [10]. Lipophilic cations with delocalized charges are 
known to accumulate in mitochondria due to the negative membrane potential. A strategy 
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for IDB selectivity that exploits the difference in membrane potential in normal versus 
cancer cells would be to create mitochondrial drugs with optimal physicochemical 
properties for accumulation in mitochondria. Several theoretical models for 
physicochemical properties that maximize mitochondrial accumulation have been 
proposed [11], and can aid in the design or optimization of drugs with optimal 
mitochondriotropic properties. Cancer cells with hyperpolarized mitochondria would be 
expected to accumulate a greater amount of such compounds than normal cells with 
normal polarization of mitochondrial membranes. Using this approach, higher 
concentrations of mitochondrial poisons can be delivered to the cancer cells relative to 
normal cells, leading to selective tumor cell killing. 
Successful evaluation of this mitochondria-centered approach to IDB selectivity 
would likely open up new frontiers into IDB selectivity. For example co-administering 
two drugs, one with IDB selectivity that exploits defective lysosomal acidification, and 
another with IDB selectivity that exploits mitochondrial hyperpolarization can enhance 
the observed selectivity even further. Hopefully, such studies may provide a driving force 
for the investigation of further sub-cellular differences in cancer versus normal cells that 
could be exploited to develop anticancer agents with enhanced selectivity dues to 
differences in influence intracellular distribution of drugs. Such differences could be 
identified using a high-throughput evaluation of intracellular drug localization differences 
between normal and cancer cells, for example, using fluorescence microscopy to 
investigate differences in intracellular localization of fluorophores. 
In summary, the work presented in this thesis has shown that intracellular drug 
distribution is a feasible avenue to enhancing the selectivity of anticancer drugs. For this 
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reason, research efforts should be made to systematically identify differences in 
intracellular properties between normal and cancer cells that can be exploited to enhance 
selectivity. Our results show that not only is this possible, but that selectivity can be 
optimized further by optimizing the physicochemical properties of drugs that are 
candidates for IDB selectivity. It is therefore hoped that the information obtained in this 
thesis provides a rationale, and guiding principles for exploration of IDB selectivity as a 
viable tumor targeting approach.  
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